var title_f13_2_13344="Hand-foot-and-mouth disease - buccal";
var content_f13_2_13344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13344=[""].join("\n");
var outline_f13_2_13344=null;
var title_f13_2_13345="Mecysteine: International drug information";
var content_f13_2_13345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mecysteine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acthiol (BR);",
"     </li>",
"     <li>",
"      Actiol (IT);",
"     </li>",
"     <li>",
"      Chistait (JP);",
"     </li>",
"     <li>",
"      Epecoal (JP);",
"     </li>",
"     <li>",
"      Moltanine (JP);",
"     </li>",
"     <li>",
"      Pectite (JP);",
"     </li>",
"     <li>",
"      Pelmain (JP);",
"     </li>",
"     <li>",
"      Visclair (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Mecysteine Hydrochloride;",
"     </li>",
"     <li>",
"      Methyl Cysteine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mucolytic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce sputum viscosity",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children &gt;5 years: 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 100-200 mg 3-4 times/day before meals; reduce to 200 mg twice daily after 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justified;\">",
"     Prophylaxis: 100-200 mg 2-3 times every other day during winter months",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as hydrochloride: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10412 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13345=[""].join("\n");
var outline_f13_2_13345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303699\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979469\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979471\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979474\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979470\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821119\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979473\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10412\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10412|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13346="Patient information: Atrophic vaginitis (The Basics)";
var content_f13_2_13346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/27/40370\">",
"         Patient information: Menopause (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/17/11538\">",
"         Patient information: Sex problems in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/33/36370\">",
"         Patient information: Vulvar pain (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/59/26546\">",
"         Patient information: Menopause (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/4/32835\">",
"         Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/23/7537\">",
"         Patient information: Vaginal dryness (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Atrophic vaginitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/atrophic-vaginitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2775873\">",
"      <span class=\"h1\">",
"       What is atrophic vaginitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atrophic vaginitis is a condition that causes the vagina and tissues near the vagina to get dry, thin, and inflamed. This can be uncomfortable or make sex painful.",
"     </p>",
"     <p>",
"      Atrophic vaginitis happens when a woman does not make enough of a hormone called estrogen. This condition mainly affects women who have been through menopause (meaning they have stopped having a monthly period). It can also happen to women whose ovaries were removed, who are taking certain medicines, or who are nursing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775888\">",
"      <span class=\"h1\">",
"       What are the symptoms of atrophic vaginitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vaginal dryness",
"       </li>",
"       <li>",
"        Vaginal burning or irritation",
"       </li>",
"       <li>",
"        Making less lubrication during sex",
"       </li>",
"       <li>",
"        Pain during sex",
"       </li>",
"       <li>",
"        Bleeding from the vagina, for example after sex. (If you have this symptom, be sure to see a doctor.)",
"       </li>",
"       <li>",
"        Vaginal discharge (leaking fluid from the vagina)",
"       </li>",
"       <li>",
"        Urinary problems, such as having to urinate often, having pain with urination, or having blood in the urine. (If you have these symptoms, be sure to see a doctor.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women never tell their doctor they are having symptoms of atrophic vaginitis. Often they are embarrassed or think the symptoms are a normal part of aging. If you have symptoms of this condition, and they bother you, mention it to your doctor or nurse. There are treatments that can help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775903\">",
"      <span class=\"h1\">",
"       Is there a test for atrophic vaginitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775918\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some women feel better if they use lubricants before sex and use a vaginal moisturizer, such as Replens&reg; or Lubrin&reg;, several times a week. Vaginal moisturizers are not the same as lubricants. They help keep the vagina moist all the time, not just during sex. Also, keep in mind that having sex can help keep the vagina healthy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775932\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have symptoms of atrophic vaginitis and they bother you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775962\">",
"      <span class=\"h1\">",
"       How is atrophic vaginitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most effective treatment for atrophic vaginitis is the hormone estrogen. When using estrogen to treat atrophic vaginitis, doctors recommend &ldquo;vaginal estrogen.&rdquo; Vaginal estrogen any form of estrogen that goes directly into the vagina. It comes in creams, tablets, or a flexible ring. Vaginal estrogen comes in small doses that don&rsquo;t increase the levels of estrogen in other parts of the body very much.",
"     </p>",
"     <p>",
"      Estrogen also comes in a pill that you swallow or a skin patch, but vaginal estrogen is better for treating symptoms of atrophic vaginitis. Some women who take vaginal estrogen must also take another hormone, called progesterone.",
"     </p>",
"     <p>",
"      If you want to take estrogen, ask your doctor or nurse what the possible risks and benefits are for you. If you have a history of breast cancer, ask whether hormones are safe for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2775947\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       Patient information: Menopause (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=see_link\">",
"       Patient information: Sex problems in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=see_link\">",
"       Patient information: Vulvar pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=see_link\">",
"       Patient information: Menopause (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=see_link\">",
"       Patient information: Vaginal dryness (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/2/13346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17105 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13346=[""].join("\n");
var outline_f13_2_13346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775873\">",
"      What is atrophic vaginitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775888\">",
"      What are the symptoms of atrophic vaginitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775903\">",
"      Is there a test for atrophic vaginitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775918\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775932\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775962\">",
"      How is atrophic vaginitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2775947\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/17/11538?source=related_link\">",
"      Patient information: Sex problems in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7537?source=related_link\">",
"      Patient information: Vaginal dryness (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/33/36370?source=related_link\">",
"      Patient information: Vulvar pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13347="Crossed cerebellar diaschesis in epilepsy";
var content_f13_2_13347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crossed cerebellar diaschesis in a patient with right hemispheric seizures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images obtained from a 38 year old patient who presented with recurrent right hemispheric seizures. Panels A and B show abnormal signal on fluid attenuated inversion recovery (FLAIR) images in the ipsilateral cortical ribbon and in the contralateral cerebellar hemisphere. Panels C and D show reduced diffusion on diffusion weighted images in corresponding regions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright &copy;2004 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13347=[""].join("\n");
var outline_f13_2_13347=null;
var title_f13_2_13348="Vulvar cancer 1";
var content_f13_2_13348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small (T1) vulvar carcinoma at the posterior fourchette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berek JS, Hacker NF. Berek &amp; Hacker's Gynecologic Oncology,&nbsp;5th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13348=[""].join("\n");
var outline_f13_2_13348=null;
var title_f13_2_13349="MRI sacral ala insufficiency fracture";
var content_f13_2_13349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of sacral ala insufficiency fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain x-rays and a CT of the pelvis failed to reveal any fracture in the elder patient for whom the studies were obtained. When her groin and low back pain persisted, this and the accompanying MRI image were obtained. Bone marrow edema consistent with an insufficiency fracture of the sacral ala (arrow) is seen on this T2 image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13349=[""].join("\n");
var outline_f13_2_13349=null;
var title_f13_2_13350="Magnesium hydroxide and mineral oil emulsion: Drug information";
var content_f13_2_13350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium hydroxide and mineral oil emulsion: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/32/12804?source=see_link\">",
"    see \"Magnesium hydroxide and mineral oil emulsion: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phillips'&reg; M-O [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Laxative: OTC labeling: Oral: 45-60 mL at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Laxative: OTC labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 20-30 mL at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute should be monitored by serum magnesium levels.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Phillips'&reg; M-O: Magnesium hydroxide 300 mg and mineral oil 1.25 mL per 5 mL (360 mL, 780 mL) [contains magnesium 125 mg and sodium 1.5 mg per 5 mL mint flavors]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before using. Do not take with meals. Dose should be followed by 8 oz of liquid.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of occasional constipation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4797233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity magnesium hydroxide, mineral oil, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4797234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use magnesium with caution in patients with severe renal impairment (especially when doses are &gt;50 mEq magnesium/day); hypermagnesemia and toxicity may occur due to decreased renal clearance of absorbed magnesium. Decreased renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) may result in toxicity; monitor for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Patients should notify healthcare provider of any sudden change in bowel habits which last &gt;14 days, stomach pain, nausea, vomiting, or if use is needed for &gt;1 week. Not for OTC use in children &lt;6 years of age, in pregnant or bedridden patients, or patients with dysphagia. Avoid concomitant use with stool softener laxatives.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, mineral oil may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant oral administration of mineral oil and multivitamins when possible; consider separating the administration of these agents by several hours to minimize the risk of interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: Mineral Oil may decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Mineral Oil may decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs.  Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4797237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Laxative: 30 minutes to 6 hours hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Magnesium: Urine (up to 30% as absorbed magnesium ions); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10123 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13350=[""].join("\n");
var outline_f13_2_13350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190953\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190963\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190960\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190957\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190947\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190937\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190950\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190949\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4797233\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4797234\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299635\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287017\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287018\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732705\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4797237\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10123|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/32/12804?source=related_link\">",
"      Magnesium hydroxide and mineral oil emulsion: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13351="Tirofiban: Drug information";
var content_f13_2_13351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tirofiban: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24611?source=see_link\">",
"    see \"Tirofiban: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrastat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrastat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI):",
"     </b>",
"     I.V.: Initial rate of 0.4 mcg/kg/minute for 30 minutes and then continued at 0.1 mcg/kg/minute. Dosing should be continued through angiography and for 12-24 hours after angioplasty or atherectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Percutaneous coronary intervention (PCI) (unlabeled use):",
"     </b>",
"     I.V.: Loading dose: 25 mcg/kg over 3 minutes at the time of PCI; Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18-24 hours (Levine, 2011; Valgimigli, 2008; Van&rsquo;t Hof, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose to 50% of normal rate.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aggrastat&reg;: 50 mcg/mL (100 mL [DSC], 250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intended for intravenous delivery using sterile equipment and technique. Do not add other drugs or remove solution directly from the bag with a syringe. Do not use plastic containers in series connections; such use can result in air embolism by drawing air from the first container if it is empty of solution. Discard unused solution 24 hours following the start of infusion. May be administered through the same catheter as heparin. Tirofiban injection must be diluted to a concentration of 50 mcg/mL (premixed solution does not require dilution). For unstable angina/non-ST-elevation MI (UA/NSTEMI), infuse loading dose over 30 minutes, followed by continuous infusion. When used during percutaneous coronary intervention (PCI), may administer loading dose over 3 minutes, followed by continuous infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F228371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, argatroban, atropine, bivalirudin, dobutamine, dopamine, epinephrine, famotidine, furosemide, heparin, lidocaine, midazolam, morphine, nitroglycerin, potassium chloride, propranolol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Tenecteplase.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute coronary syndrome (ie, unstable angina/non-ST-elevation myocardial infarction [UA/NSTEMI]) in combination with heparin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9838264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To support PCI (administered at the time of PCI) for ST-elevation myocardial infarction (STEMI), UA/NSTEMI, and stable ischemic heart disease (ie, elective PCI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aggrastat&reg; may be confused with Aggrenox&reg;, argatroban",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding is the major drug-related adverse effect. Patients received background treatment with aspirin and heparin. Major bleeding was reported in 1.4% to 2.2%; minor bleeding in 10.5% to 12%; transfusion was required in 4% to 4.3%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;1% (nonbleeding adverse events):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular:  Coronary artery dissection (5%), bradycardia (4%), edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%), vasovagal reaction (2%), fever (&gt;1%), headache (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia: &lt;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (1.5%), &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (0.3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acutely decreased platelets in association with fever, anaphylaxis, GI bleeding (0.1% to 0.2%), GU bleeding (up to 0.1%), hemopericardium, intracranial bleeding (up to 0.1%), pulmonary alveolar hemorrhage, rash, retroperitoneal bleeding (up to 0.6%), severe (&lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) thrombocytopenia (rare), spinal-epidural hematoma",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tirofiban or any component of the formulation; active internal bleeding or a history of bleeding diathesis within the previous 30 days; history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm; history of thrombocytopenia following prior exposure; history of CVA within 30 days or any history of hemorrhagic stroke; major surgical procedure or severe physical trauma within the previous month; history, symptoms, or findings suggestive of aortic dissection; severe hypertension (systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110 mm Hg); concomitant use of another parenteral GP IIb/IIIa inhibitor; acute pericarditis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; watch closely for bleeding, especially the arterial access site for the cardiac catheterization. Use with extreme caution in patients with platelet counts &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , patients with hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy and in chronic dialysis patients. Use caution with administration of other drugs affecting hemostasis. Minimize other procedures including arterial and venous punctures, I.M. injections, nasogastric tubes, etc.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Adjust the dose with severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Percutaneous coronary intervention: Sheath removal: Prior to pulling the sheath, heparin should be discontinued for 3-4 hours and ACT &lt;180 seconds or aPTT &lt;45 seconds. Use standard compression techniques after sheath removal. Watch the site closely afterwards for further bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Discontinue at least 2-4 hours prior to coronary artery bypass graft surgery (Hillis, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Information related to use in pregnancy is limited; successful use during pregnancy has been described in a case report (Boztosun, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aggrastat Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/500 mL 0.9% (100 mL): $296.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet count. Hemoglobin and hematocrit should be monitored prior to treatment, within 6 hours following loading infusion, and at least daily thereafter during therapy. Platelet count may need to be monitored earlier in patients who received prior glycoprotein IIb/IIa antagonists. Persistent reductions of platelet counts &lt;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     may require interruption or discontinuation of infusion. Because tirofiban requires concurrent heparin therapy, aPTT levels should also be followed. Monitor vital signs and laboratory results prior to, during, and after therapy. Assess infusion insertion site during and after therapy (every 15 minutes or as institutional policy). Observe and teach patient bleeding precautions (avoid invasive procedures and activities that could result in injury). Monitor closely for signs of unusual or excessive bleeding (eg, CNS changes, blood in urine, stool, or vomitus, unusual bruising or bleeding). Breast-feeding is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrastat (AT, AU, BB, BE, BG, BM, BS, BZ, CH, CL, CZ, DE, DK, EE, FI, GB, GR, GY, HK, HU, IE, IL, IN, IT, JM, MY, NL, NO, NZ, PH, PK, PL, PR, PT, SE, SG, SR, TR, TT, TW);",
"     </li>",
"     <li>",
"      Agrastat (AR, BR, CN, CO, CR, EC, ES, FR, GT, HN, KP, MX, NI, PA, PE, SV, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, it inhibits",
"     <i>",
"      ex vivo",
"     </i>",
"     platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, &gt;90% inhibition is attained by the end of the 30-minute infusion. Platelet aggregation inhibition is reversible following cessation of the infusion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 35% unbound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (65%) and feces (25%) primarily as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Elderly: Reduced by 19% to 26%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Comparison of Aspirin Plus Tirofiban With Aspirin Plus Heparin for Unstable Angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(21):1498-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9599104/pubmed\" id=\"9599104\" target=\"_blank\">",
"        9599104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Giugliano RP, Gibson CM, et al, &ldquo;Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(21):2720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10351964/pubmed\" id=\"10351964\" target=\"_blank\">",
"        10351964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boztosun B, Olcay A, Avci A, et al, \"Treatment of Acute Myocardial Infarction in Pregnancy With Coronary Artery Balloon Angioplasty and Stenting: Use of Tirofiban and Clopidogrel,\"",
"      <i>",
"       Int J Cardiol",
"      </i>",
"      , 2008, 127(3):413-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/17655948/pubmed\" id=\"17655948\" target=\"_blank\">",
"        17655948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brener SJ, Barr LA, Burchenal JE, et al, &ldquo;Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,&rdquo; ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators,",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(8):734-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al, &ldquo;Comparison of Early Invasive and Conservative Strategies in Patients With Unstable Coronary Syndromes Treated With the Glycoprotein IIb/IIIa Inhibitor Tirofiban,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(25):1879-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/11419424/pubmed\" id=\"11419424\" target=\"_blank\">",
"        11419424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demirkan B, Guray Y, Guray U, et al, &ldquo;Differential Diagnosis and Management of Acute Profound Thrombocytopenia by Tirofiban: A Case Report,&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2006, 22(1):77-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/16786237/pubmed\" id=\"16786237\" target=\"_blank\">",
"        16786237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 96(5):1445-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9315530/pubmed\" id=\"9315530\" target=\"_blank\">",
"        9315530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giugliano RP, White JA, Bode C, et al, &ldquo;Early Versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(21):2176-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/19332455/pubmed\" id=\"19332455\" target=\"_blank\">",
"        19332455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamm CW, Heeschen C, Goldmann B, et al, &ldquo;Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(21):1623-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10341274/pubmed\" id=\"10341274\" target=\"_blank\">",
"        10341274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huxtable LM, Tafreshi MJ, and Rakkar AN, &ldquo;Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2006, 97(3):426-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/16442410 /pubmed\" id=\"16442410 \" target=\"_blank\">",
"        16442410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor With Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(21):1488-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9599103/pubmed\" id=\"9599103\" target=\"_blank\">",
"        9599103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(7):436-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9705684/pubmed\" id=\"9705684\" target=\"_blank\">",
"        9705684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Anderson KM, et al, &ldquo;Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(1):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9207636/pubmed\" id=\"9207636\" target=\"_blank\">",
"        9207636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Moliterno DJ, et al, &ldquo;Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(5):319-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10423466/pubmed\" id=\"10423466\" target=\"_blank\">",
"        10423466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Tcheng JE, Califf RM, et al, &ldquo;Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(15):1951-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10208997/pubmed\" id=\"10208997\" target=\"_blank\">",
"        10208997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Llevadot J, Coulter SA, and Giugliano RP, &ldquo;A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2000, 9(2):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10613999/pubmed\" id=\"10613999\" target=\"_blank\">",
"        10613999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, Ferguson JJ, Weisman HF, et al, &ldquo;Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta",
"      <sub>",
"       3",
"      </sub>",
"      Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 278(6):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/9256222/pubmed\" id=\"9256222\" target=\"_blank\">",
"        9256222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, Moliterno DJ, Herrmann HC, et al, &ldquo;Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(25):1888-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/11419425/pubmed\" id=\"11419425\" target=\"_blank\">",
"        11419425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Merkhof LF, Zijlstra F, Olsson H, et al, &ldquo;Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(6):1528-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/10334418/pubmed\" id=\"10334418\" target=\"_blank\">",
"        10334418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valgimigli M, Campo G, Percoco G, et al, &ldquo;Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-eluting or Uncoated Stents for Acute Myocardial Infarction: the MULTISTRATEGY Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(15):1788-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/18375998/pubmed\" id=\"18375998\" target=\"_blank\">",
"        18375998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valgimigli M, Percoco G, Malagutti P, et al, &ldquo;Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 293(17):2109-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/15870414/pubmed\" id=\"15870414\" target=\"_blank\">",
"        15870414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van&rsquo;t Hof AW, ten Berg J, Heestermans T, et al, &ldquo;Prehospital Initiation of Tirofiban in Patients with ST-elevation Myocardial Infarction Undergoing Primary Angioplasty (On-TIME 2): A Multicenter, Double-Blind, Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 372(9638):537-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/2/13351/abstract-text/18707985/pubmed\" id=\"18707985\" target=\"_blank\">",
"        18707985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10288 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13351=[""].join("\n");
var outline_f13_2_13351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228333\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228334\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228365\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228338\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228339\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228340\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228316\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228301\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228319\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228371\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228317\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838264\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228373\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228363\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228322\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228305\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300145\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228310\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228312\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079798\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228344\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323993\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228314\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228324\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228304\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228321\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10288|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24611?source=related_link\">",
"      Tirofiban: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13352="Red blood cell membrane dynamics and organization";
var content_f13_2_13352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Red blood cell membrane dynamics and organization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Mohandas Narla, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13352/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/2/13352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma membrane of the red blood cell (RBC) consists of a complex, ordered array of lipids and proteins stretched over the outer surface of the cell in the form of a lipid bilayer punctuated by penetrating or attached proteins (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ). This membrane, as with other biologic membranes, has numerous properties that arise in part from specialized interactions between specific membrane proteins or lipids, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three features of the red cell membrane stand out:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma membranes are noncovalent assemblies of billions of molecules, yet they tend to be self-assembling, self-sealing, and stable. A typical cell plasma membrane contains a billion lipid molecules and 10 million protein molecules. All these molecules are associated as an extraordinarily thin (6 to 10 nm), continuous sheet-like membrane enveloping the cell.",
"     </li>",
"     <li>",
"      Plasma membranes are fluid structures, yet they are highly ordered with respect to the distribution of molecules both across the bilayer and within the plane of the bilayer. As a result, the distribution of both membrane lipids and proteins is highly asymmetric.",
"     </li>",
"     <li>",
"      Plasma membranes function as a barrier, yet they readily pass ions (some against a concentration gradient), nutrients, and information (signals) between the cytoplasm and the extracellular environment. Information transfer often occurs without transmembrane molecular passage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general properties of the RBC membrane will be reviewed here, with emphasis on the principles that underlie its assembly and function and on factors that establish and maintain order within the membrane. Other issues related to RBC function&mdash;the deformability and stability of the cell, and control of cell hydration&mdash;are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURAL REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human red cell leaves the bone marrow in the form of the reticulocyte; within one day, or up to 2.5 days in the presence of anemia, the circulating reticulocyte becomes a mature erythrocyte. Mature erythrocytes that are 7 to 8 microns in diameter must elongate, tank tread, and otherwise deform to pass through 3 micron diameter capillaries and 2 to 3 micron slits in the reticuloendothelial sinusoids (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, during its 120-day life span, the erythrocyte must undergo extensive passive deformation and must be stable to resist fragmentation. The ability of the red cell to undergo extensive deformation is essential for both its function and its survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Red cell deformability is a function of its geometry, the viscosity of the intracellular milieu, and the material properties of the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The RBC is unique among eukaryotic cells in that its principal physical structure is its membrane, which encloses a concentrated hemoglobin solution. Thus, all of the structural properties of this cell are in one way or another linked to the cell membrane. In contrast to other cells, the RBC has no cytoplasmic structures or organelles and does not have a nucleus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STRUCTURAL ORGANIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RBC membrane is composed of a lipid bilayer to which is anchored a filamentous network of proteins that underlies the cytoplasmic surface of the membrane. This network, also referred to as the membrane skeleton or cytoskeleton, is important for maintaining cell shape and regulating the membrane properties of deformability and mechanical stability (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lipid bilayer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of the lipid bilayer is to provide physical continuity to the membrane, which is responsible for solute impermeability. The lipid bilayer also serves as the matrix in which the transmembrane proteins reside.",
"   </p>",
"   <p>",
"    The shape of the lipid bilayer is responsive to slight variations in the surface area of either the inner or outer leaflet [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Increasing the surface area of the inner leaflet produces a stomatocytic shape change while increasing that of the outer leaflet promotes outward curvature and transforms the cell into an echinocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"     \"Stomatocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Membrane lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structural organization of the various lipid and protein components of the red cell membrane has been well described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/11-20\">",
"     11-20",
"    </a>",
"    ]. Approximately 52 percent of the membrane mass is protein, 40 percent is lipid, and 8 percent is carbohydrate. The major lipid components of the RBC membrane are unesterified cholesterol and phospholipids, which are present in nearly equimolar quantities, and small amounts of free fatty acids and glycolipids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The membrane phospholipid primarily consists of phosphatidylcholine (PC, 30 percent), sphingomyelin (SM, 25 percent), phosphatidylethanolamine (PE, 28 percent), and phosphatidylserine (PS, 14 percent). These phospholipids are asymmetrically distributed in the membrane: more than 75 percent of the choline-containing uncharged phospholipids PC and SM are in the outer monolayer of the lipid bilayer, while 80 percent of PE and all of the PS, the charged phospholipids, reside in the inner monolayer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maintenance of asymmetric phospholipid distribution in the normal RBC membrane appears to be a function of the following processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A slow and symmetric rate of passive diffusion of choline-containing phospholipids (PC and SM) across the two lipid monolayers (half-times on the order of hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, cholesterol diffuses across the membrane on a physiologic time scale (half-time of seconds or less) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A direct interaction between charged phospholipids and membrane skeletal proteins.",
"     </li>",
"     <li>",
"      Active transport of the aminophospholipids (PS and PE) by an ATP-dependent aminophospholipid translocase or \"flippase\" from the outer to the inner monolayer [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/13,22,23\">",
"       13,22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An example of partial loss of this organization occurs in beta thalassemic and sickle cell RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In some beta thalassemic and sickle RBCs, the membrane phospholipid bilayer is scrambled in such a way that some PS moves to the outer leaflet [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This abnormality, which is presumably due to oxidative injury caused by aggregates of excess alpha globin chains in beta thalassemia, may be importantly clinically, since PS on the outer leaflet may be recognized by macrophages as a signal for attachment and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/28\">",
"     28",
"    </a>",
"    ], contributing to thrombogenesis, endothelial adhesion, and a reduction in RBC survival.",
"   </p>",
"   <p>",
"    By a similar mechanism, PS on the outer leaflet may provide a signal for macrophage removal of apoptotic erythroid precursors in the marrow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mature RBC is unable to synthesize lipids de novo. However, lipid renewal pathways produce considerable turnover of the various phospholipids with no net change in lipid composition. In addition, the cholesterol content of the membrane is regulated by exchange between plasma cholesterol and membrane cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Types of membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of proteins of the red cell membrane by sodium dodecyl",
"    <span class=\"nowrap\">",
"     sulfate/polyacrylamide",
"    </span>",
"    gel electrophoresis",
"    <span class=\"nowrap\">",
"     (SDS/PAGE)",
"    </span>",
"    indicates the presence of about a dozen distinct species. By contrast, separation employing isoelectric focusing in one dimension and",
"    <span class=\"nowrap\">",
"     SDS/PAGE",
"    </span>",
"    in the other shows the membrane to be composed of more than 100 different proteins, some of which are yet to be characterized.",
"   </p>",
"   <p>",
"    The membrane proteins are divided into two general groups: integral and peripheral proteins (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The integral proteins are tightly embedded in the membrane through hydrophobic interactions with the lipids in the bilayer. Band 3 (the anion exchanger), aquaporin-1 (the water channel), Glut-1 (glucose transporter), and glycophorins are the most abundant proteins of this class. These proteins span the membrane and have distinct structural and functional domains, both within the bilayer and on either side of the membrane.",
"     </li>",
"     <li>",
"      The peripheral proteins are located on the cytoplasmic surface of the lipid bilayer and can be readily released from the membrane by manipulation of ionic strength of the milieu or other protein perturbants. These proteins constitute the membrane skeleton and include spectrin, actin, protein 4.1, band 4.2, ankyrin, adducin, dematin, tropomyosin, and tropomodulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Integral membrane proteins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Band 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Band 3, the anion exchanger (AE1), is the major integral protein, constituting about 25 percent of total membrane protein. Each red cell contains approximately one million copies of band 3.",
"   </p>",
"   <p>",
"    Band 3 is the product of a gene residing on chromosome 17 that encodes a 911-amino acid protein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/30\">",
"     30",
"    </a>",
"    ]. The gene is transcribed by two promoters: the upstream promoter produces erythroid band 3 while the downstream promoter produces renal band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/31\">",
"     31",
"    </a>",
"    ]. Defects in the production of renal band 3 account for some cases of familial distal (type 1) renal tubular acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Band 3 is composed of three dissimilar and functionally distinct domains. The hydrophilic cytoplasmic domain (residues 1 to 403) interacts with a variety of peripheral membrane and cytoplasmic proteins, including ankyrin, protein 4.1, protein 4.2, adducin, hemoglobin, and a number of glycolytic enzymes. The hydrophobic transmembrane domain (residues 404 to 882) contains multiple membrane spanning domains and forms the anion transporter. The acidic C-terminal domain (residues 883 to 911) has no known function although evidence suggests that this domain can bind carbonic anhydrase.",
"   </p>",
"   <p>",
"    Band 3 also contains a single N-glycosidically linked oligosaccharide that possesses the blood group antigen activities I and i [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/32\">",
"     32",
"    </a>",
"    ], and carries low incidence blood group antigens belonging to the Diego system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two clearly established functions of band 3 in the RBC membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anion transport, resulting in one-for-one exchange of bicarbonate for chloride across the membrane. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"       \"Control of red blood cell hydration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical linkage of the lipid bilayer to the underlying membrane skeleton, primarily through its interaction with ankyrin and protein 4.2 and secondarily through binding to protein 4.1 and adducin (",
"      <a class=\"graphic graphic_figure graphicRef61578 \" href=\"UTD.htm?12/48/13058\">",
"       figure 2",
"      </a>",
"      ). The main function of band 3 in this regard appears to be prevention of membrane surface loss rather than assembly of the membrane skeleton. Thus, targeted mutagenesis to generate RBCs without band 3 results in spherocytosis and hemolysis but no change in the skeletal architecture or components [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/31,34\">",
"       31,34",
"      </a>",
"      ]. Similarly, band 3 defects are responsible for 15 to 25 percent of cases of hereditary spherocytosis in humans, a disorder that is associated with progressive RBC membrane loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Band 3 defects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glycophorins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four sialic acid-rich glycoproteins (glycophorin A, B, C, and D) comprise a class of integral proteins that constitute approximately 2 percent of the total red cell membrane proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/35\">",
"     35",
"    </a>",
"    ]. Glycophorins A, B, and C are distinctly different polypeptides, which are the product of distinct genes. The genes coding for glycophorins A and B reside on chromosome 4 while glycophorin C is encoded by a gene residing on chromosome 2 and the same gene encodes glycophorin D from a downstream initiation site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glycophorins consist of three domains: a cytoplasmic domain, containing a cluster of basic residues positioned near the plasma membrane; a hydrophobic domain, which forms a single alpha-helix spanning the bilayer; and an extracellular domain, which is heavily glycosylated. The glycophorin A molecule carries the MN blood group specificity, glycophorin B the Ss specificity, and glycophorin C the Gerbich blood group specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of carbohydrates in the glycophorins imparts a strong net negative charge to the cell surface; this is functionally important in reducing the interaction of red cells with one another and with other cells, including vascular endothelium. Glycophorin C appears to interact with p55 and protein 4.1; through this association, it regulates the membrane content of these proteins. A normal glycophorin",
"    <span class=\"nowrap\">",
"     C/protein",
"    </span>",
"    <span class=\"nowrap\">",
"     4.1/p55",
"    </span>",
"    complex appears to be important for Plasmodium falciparum invasion of and development in RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Resistance to malaria'",
"    </a>",
"    .) Glycophorin A is also a receptor for P. falciparum invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other integral proteins are present in the red cell membrane.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aquaporin-1 &mdash; Aquaporin-1 belongs to a family of membrane channel proteins that serve as selective pores for water transport [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/38\">",
"       38",
"      </a>",
"      ]. These proteins allow the red cell to remain in osmotic equilibrium with the extracellular fluid. In addition, the Colton blood group antigens represent a polymorphism on the aquaporin-1 protein [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rh blood group antigens &mdash; Of the different human red cell surface antigens, the Rh blood group system is unique in that its antigens are carried by a family of nonglycosylated but palmitoylated membrane proteins comprised of Rh30 (RhD and RhCE) polypeptides and the Rh50 glycoprotein [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/40\">",
"       40",
"      </a>",
"      ]. The function of this protein complex remains undefined, although evidence suggests that it may be a gas transporter. Other blood group-specific determinants on the red cell membrane include, Duffy, Kell, Kidd, Lutheren and Lewis. Although the function of these proteins remains to be defined, it is likely that some of these integral proteins possess transport functions while others are involved in either mediating adhesive interactions or in linking bilayer to the membrane skeleton.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peripheral membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The filamentous network of peripheral proteins is anchored to the bilayer via interactions with several integral proteins. This network, generally referred to as the membrane skeleton, underlies the lipid bilayer; it is largely responsible for membrane elasticity and membrane mechanical stability of the red cell [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. It is composed of the following major components: spectrin, actin, protein 4.1, band 4.2, ankyrin, adducin, dematin, tropomyosin, and tropomodulin.",
"   </p>",
"   <p>",
"    The red cell membrane skeleton can be envisioned as an irregular network in which the basic unit is composed of a hexagonal lattice with six spectrin molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/17,41\">",
"     17,41",
"    </a>",
"    ]. High resolution electron micrographs show a highly repeated and remarkably regular organization of",
"    <span class=\"nowrap\">",
"     spectrin/actin/protein",
"    </span>",
"    4.1 complexes in which each complex is linked to adjacent complexes by multiple spectrin tetramers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/42\">",
"     42",
"    </a>",
"    ]. In comparison, ankyrin is the major protein that physically links the lipid bilayer to the membrane skeleton through its interaction with membrane band 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with band 3 deficiency described above, defects in some of these proteins, particularly ankyrin, spectrin, and protein 4.1, lead to a mechanically unstable membrane, producing RBC fragmentation and the generation of cells with reduced surface area, and resulting in congenital hemolytic anemias, such as hereditary spherocytosis and hereditary elliptocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Spectrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectrin is a flexible, rod-like molecule present in red cells at approximately 200,000 copies per cell. It is composed of two nonidentical subunits, alpha-spectrin and beta-spectrin that are intertwined side to side. The gene that codes for alpha-spectrin resides on chromosome 1 and that for beta-spectrin is on chromosome 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrin subunits are linked by flexible joining regions like beads on a string. Spectrin heterodimers associate head to head to form (alpha-beta)2 tetramers. Tetrameric species of spectrin appear to predominate in the membrane skeleton. Synthesis of beta-spectrin is rate limiting for the assembly of the spectrin tetramer, while alpha-spectrin is synthesized in excess. Thus, deficiency or dysfunction of a single beta-spectrin allele is sufficient to cause spherocytosis (dominant inheritance) while both alpha-spectrin alleles must be affected to cause the same phenotypic disease (recessive inheritance). Oligomers larger than the tetramers are also observed; they appear to be formed by spectrin dimers joined by head-to-head linkages into a central ring [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta spectrin has several binding sites for attachment to other membrane proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Near the C-terminus of beta spectrin is an attachment site for ankyrin, which also binds to the cytoplasmic tail of band 3, which provides the major linkage between the lipid bilayer and the membrane skeleton [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Near the tail end (N-terminus) of beta spectrin is an attachment site for protein 4.1, which, through its association with glycophorin C, provides a second anchoring point connecting the lipid bilayer and the membrane skeleton [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The N-terminal region of beta spectrin has binding sites for multiple short actin filaments and protein 4.1, forming a junctional complex [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Actin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell actin is unusual in being organized into short, highly uniform filaments of approximately 35 nm in length. The length of actin filaments may be modulated by the proteins tropomyosin and tropomodulin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tail ends of the spectrin tetramers are associated with short oligomers of actin. On average, six spectrin ends complex with each actin oligomer, creating an irregular network with an approximately hexagonal lattice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/17,41\">",
"     17,41",
"    </a>",
"    ]. Each spectrin-actin junction is stabilized by the formation of a ternary complex with protein 4.1 and to a lesser degree adducin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Protein 4.1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene coding for protein 4.1 has been sequenced and localized to chromosome 1. The protein is composed of 622 amino acids; approximately 200,000 copies of this molecule are present in each red cell. Spectrin-actin interactions that are independently weak are greatly stabilized by protein 4.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/47\">",
"     47",
"    </a>",
"    ]. Stabilization occurs through direct interaction of protein 4.1 with both spectrin and actin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Adducin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adducin also stabilizes the interaction of spectrin with actin. Newer studies of the red cell membrane have demonstrated the existence of a novel band 3-adducin-spectrin bridge that connects the",
"    <span class=\"nowrap\">",
"     spectrin/actin/protein",
"    </span>",
"    4.1 junctional complex to the lipid bilayer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adducin is much less abundant than protein 4.1, with only 30,000 molecules present in each red cell. Adducin is a target for the calcium-dependent regulating protein, calmodulin; as a result, its ability to promote spectrin-actin interactions is regulated by the intracellular calcium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ankyrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanical coupling of the membrane skeleton to the lipid bilayer is primarily accomplished by ankyrin (band 2.1), which simultaneously interacts with spectrin in the skeleton and band 3 in the bilayer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/17,19,45\">",
"     17,19,45",
"    </a>",
"    ]. This linkage is strengthened by protein 4.2, which binds to both band 3 and to ankyrin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene coding for ankyrin has been sequenced and localized to chromosome 8. Ankyrin contains 1879 amino acids. It has distinct binding sites for both beta-spectrin and band three and is present in the red cell at 100,000 copies per cell [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/19\">",
"     19",
"    </a>",
"    ]. The ankyrin-binding site on beta-spectrin is located approximately 20 nm from the C-terminus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dynamic regulation of protein interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important function of these protein assemblies is to provide the red cell with a flexible, yet mechanically resilient and stable, membrane. However, these interactions must be regulated since, during its time in the circulation, the red cell constantly undergoes cycles of deformation and relaxation, requiring the membrane to accommodate to extensive and dynamic changes in cell shape. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This is most likely accomplished by dynamic regulation of the protein interactions. Potential regulatory mechanisms include phosphorylation, variations in intracellular magnesium and 2,3-diphosphoglycerate (2,3-DPG) during the",
"    <span class=\"nowrap\">",
"     oxygenation/deoxygenation",
"    </span>",
"    cycle, and calmodulin effects due to elevated intracellular calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/17,50,51\">",
"     17,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only limited information is available regarding these regulatory pathways. Most of the available evidence suggests that phosphorylation tends to lower the affinity of protein-protein interactions. As examples, phosphorylation of protein 4.1 results in a fivefold decrease in its affinity for spectrin and in its ability to promote spectrin-actin association, while phosphorylation of beta-spectrin reduces membrane mechanical stability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/52\">",
"     52",
"    </a>",
"    ]. Similarly, increased levels of intracellular 2,3-DPG [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/50\">",
"     50",
"    </a>",
"    ] and elevated cytoplasmic concentrations of calcium, in association with calmodulin, decrease membrane mechanical stability by destabilizing spectrin-actin-protein 4.1 and spectrin-actin-adducin interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13352/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530107\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530308\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma membrane of the red blood cell (RBC) consists of a complex, ordered array of lipids and proteins stretched over the outer surface of the cell in the form of a lipid bilayer punctuated by penetrating or attached proteins (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ). Mature erythrocytes that are 7 to 8 microns in diameter must elongate, tank tread, and otherwise deform to pass through 3 micron diameter capillaries and 2 to 3 micron slits in the reticuloendothelial sinusoids (",
"    <a class=\"graphic graphic_picture graphicRef53105 \" href=\"UTD.htm?25/59/26544\">",
"     picture 1",
"    </a>",
"    ). The ability of the red cell to undergo extensive deformation is essential for both its function and its survival. Such deformability is a function of its geometry, the viscosity of the intracellular milieu, and the material properties of the membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530363\">",
"    <span class=\"h2\">",
"     Membrane lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of the membrane mass is lipid, with the major components being unesterified cholesterol and phospholipids. The phospholipids are asymmetrically distributed in the membrane. Loss of this asymmetry may be recognized by macrophages as a signal for attachment and phagocytosis, contributing to thrombogenesis, endothelial adhesion, and a reduction in RBC survival. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Structural organization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530428\">",
"    <span class=\"h2\">",
"     Membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The membrane proteins are divided into two general groups: integral and peripheral proteins (",
"    <a class=\"graphic graphic_figure graphicRef79183 \" href=\"UTD.htm?9/7/9334\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530634\">",
"    <span class=\"h3\">",
"     Integral proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integral proteins are tightly embedded in the membrane through hydrophobic interactions with the lipids in the bilayer. Band 3 (the anion exchanger), aquaporin-1 (the water channel), Glut-1 (glucose transporter), and glycophorins (blood group specificity) are the most abundant proteins of this class. Carbohydrates in the glycophorins impart a strong net negative charge to the cell surface, important in reducing the interaction of red cells with one another and with other cells, including vascular endothelium. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Integral membrane proteins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Band 3 defects are responsible for 15 to 25 percent of cases of hereditary spherocytosis in humans, a disorder that is associated with progressive RBC membrane loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Band 3 defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H530641\">",
"    <span class=\"h3\">",
"     Peripheral proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral proteins are located on the cytoplasmic surface of the lipid bilayer and are anchored to the bilayer via interactions with several integral proteins. This network (the membrane skeleton), is largely responsible for elasticity and mechanical stability of the red cell. It is composed of the following major components: spectrin, actin, protein 4.1, band 4.2, ankyrin, adducin, dematin, tropomyosin, and tropomodulin. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Peripheral membrane proteins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Defects in some of these proteins, particularly ankyrin, spectrin, and protein 4.1, lead to a mechanically unstable membrane, producing RBC fragmentation and the generation of cells with reduced surface area, and resulting in congenital hemolytic anemias, such as hereditary spherocytosis and hereditary elliptocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/1\">",
"      Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood 2008; 112:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/2\">",
"      Weed RI. The importance of erythrocyte deformability. Am J Med 1970; 49:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/3\">",
"      La Celle PL, Weed RI. The contribution of normal and pathologic erythrocytes to blood rheology. Prog Hematol 1971; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/4\">",
"      Weiss L, Tavassoli M. Anatomical hazards to the passage of erythrocytes through the spleen. Semin Hematol 1970; 7:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/5\">",
"      Mohandas N, Phillips WM, Bessis M. Red blood cell deformability and hemolytic anemias. Semin Hematol 1979; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/6\">",
"      Chien S. Red cell deformability and its relevance to blood flow. Annu Rev Physiol 1987; 49:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/7\">",
"      Mohandas N, Chasis JA. Red blood cell deformability, membrane material properties and shape: regulation by transmembrane, skeletal and cytosolic proteins and lipids. Semin Hematol 1993; 30:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/8\">",
"      Mohandas N, Evans E. Mechanical properties of the red cell membrane in relation to molecular structure and genetic defects. Annu Rev Biophys Biomol Struct 1994; 23:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/9\">",
"      Ferrell JE Jr, Lee KJ, Huestis WH. Membrane bilayer balance and erythrocyte shape: a quantitative assessment. Biochemistry 1985; 24:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/10\">",
"      Lange Y, Steck TL. Mechanism of red blood cell acanthocytosis and echinocytosis in vivo. J Membr Biol 1984; 77:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/11\">",
"      Ways P, Hanahan DJ. Characterization and quantification of red cell lipids in normal man. J Lipid Res 1964; 5:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/12\">",
"      Verkleij AJ, Zwaal RF, Roelofsen B, et al. The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy. Biochim Biophys Acta 1973; 323:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/13\">",
"      Devaux PF. Static and dynamic lipid asymmetry in cell membranes. Biochemistry 1991; 30:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/14\">",
"      Fairbanks G, Steck TL, Wallach DF. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 1971; 10:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/15\">",
"      Steck TL. The organization of proteins in the human red blood cell membrane. A review. J Cell Biol 1974; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/16\">",
"      Marchesi VT. Stabilizing infrastructure of cell membranes. Annu Rev Cell Biol 1985; 1:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/17\">",
"      Bennett V. The spectrin-actin junction of erythrocyte membrane skeletons. Biochim Biophys Acta 1989; 988:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/18\">",
"      Bennett V, Lambert S. The spectrin skeleton: from red cells to brain. J Clin Invest 1991; 87:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/19\">",
"      Bennett V. Ankyrins. Adaptors between diverse plasma membrane proteins and the cytoplasm. J Biol Chem 1992; 267:8703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/20\">",
"      Winkelmann JC, Forget BG. Erythroid and nonerythroid spectrins. Blood 1993; 81:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/21\">",
"      Lange Y, Dolde J, Steck TL. The rate of transmembrane movement of cholesterol in the human erythrocyte. J Biol Chem 1981; 256:5321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/22\">",
"      Daleke DL, Huestis WH. Incorporation and translocation of aminophospholipids in human erythrocytes. Biochemistry 1985; 24:5406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/23\">",
"      Zachowski A, Favre E, Cribier S, et al. Outside-inside translocation of aminophospholipids in the human erythrocyte membrane is mediated by a specific enzyme. Biochemistry 1986; 25:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/24\">",
"      Yasin Z, Witting S, Palascak MB, et al. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood 2003; 102:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/25\">",
"      Setty BN, Betal SG. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 2008; 111:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/26\">",
"      Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998; 91:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/27\">",
"      Barber LA, Palascak MB, Joiner CH, Franco RS. Aminophospholipid translocase and phospholipid scramblase activities in sickle erythrocyte subpopulations. Br J Haematol 2009; 146:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/28\">",
"      Allen TM, Williamson P, Schlegel RA. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc Natl Acad Sci U S A 1988; 85:8067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/29\">",
"      Shohet SB, Nathan DG, Karnovsky ML. Stages in the incorporation of fatty acids into red blood cells. J Clin Invest 1968; 47:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/30\">",
"      Lux SE, John KM, Kopito RR, Lodish HF. Cloning and characterization of band 3, the human erythrocyte anion-exchange protein (AE1). Proc Natl Acad Sci U S A 1989; 86:9089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/31\">",
"      Southgate CD, Chishti AH, Mitchell B, et al. Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Nat Genet 1996; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     Reid ME, Lomas-Francis C. The blood group antigen &mdash; facts book, Academic Press, 1997. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/33\">",
"      Jarolim P, Rubin HL, Zakova D, et al. Characterization of seven low incidence blood group antigens carried by erythrocyte band 3 protein. Blood 1998; 92:4836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/34\">",
"      Peters LL, Shivdasani RA, Liu SC, et al. Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton. Cell 1996; 86:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/35\">",
"      Chasis JA, Mohandas N. Red blood cell glycophorins. Blood 1992; 80:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/36\">",
"      Chishti AH, Palek J, Fisher D, et al. Reduced invasion and growth of Plasmodium falciparum into elliptocytic red blood cells with a combined deficiency of protein 4.1, glycophorin C, and p55. Blood 1996; 87:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/37\">",
"      Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/38\">",
"      Lee MD, King LS, Agre P. The aquaporin family of water channel proteins in clinical medicine. Medicine (Baltimore) 1997; 76:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/39\">",
"      Smith BL, Preston GM, Spring FA, et al. Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens. J Clin Invest 1994; 94:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/40\">",
"      Huang CH. Molecular insights into the Rh protein family and associated antigens. Curr Opin Hematol 1997; 4:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/41\">",
"      Liu SC, Derick LH, Palek J. Visualization of the hexagonal lattice in the erythrocyte membrane skeleton. J Cell Biol 1987; 104:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/42\">",
"      Morrow JS, Marchesi VT. Self-assembly of spectrin oligomers in vitro: a basis for a dynamic cytoskeleton. J Cell Biol 1981; 88:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/43\">",
"      Gallagher PG, Ferriera JD. Molecular basis of erythrocyte membrane disorders. Curr Opin Hematol 1997; 4:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/44\">",
"      Gallagher PG, Forget BG. Spectrin genes in health and disease. Semin Hematol 1993; 30:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/45\">",
"      Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol 1993; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/46\">",
"      Conboy JG. Structure, function, and molecular genetics of erythroid membrane skeletal protein 4.1 in normal and abnormal red blood cells. Semin Hematol 1993; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/47\">",
"      Gilligan DM, Bennett V. The junctional complex of the membrane skeleton. Semin Hematol 1993; 30:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/48\">",
"      Anong WA, Franco T, Chu H, et al. Adducin forms a bridge between the erythrocyte membrane and its cytoskeleton and regulates membrane cohesion. Blood 2009; 114:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/49\">",
"      Cohen CM, Dotimas E, Korsgren C. Human erythrocyte membrane protein band 4.2 (pallidin). Semin Hematol 1993; 30:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/50\">",
"      Chasis JA, Mohandas N. Erythrocyte membrane deformability and stability: two distinct membrane properties that are independently regulated by skeletal protein associations. J Cell Biol 1986; 103:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/51\">",
"      Liu J, Guo X, Mohandas N, et al. Membrane remodeling during reticulocyte maturation. Blood 2010; 115:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/52\">",
"      Manno S, Takakuwa Y, Nagao K, Mohandas N. Modulation of erythrocyte membrane mechanical function by beta-spectrin phosphorylation and dephosphorylation. J Biol Chem 1995; 270:5659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13352/abstract/53\">",
"      Takakuwa Y, Mohandas N. Modulation of erythrocyte membrane material properties by Ca2+ and calmodulin. Implications for their role in regulation of skeletal protein interactions. J Clin Invest 1988; 82:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7091 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13352=[""].join("\n");
var outline_f13_2_13352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H530107\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURAL REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STRUCTURAL ORGANIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lipid bilayer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Membrane lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Types of membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Integral membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Band 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glycophorins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peripheral membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Spectrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Actin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Protein 4.1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Adducin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ankyrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dynamic regulation of protein interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H530107\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530308\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530363\">",
"      Membrane lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H530428\">",
"      Membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H530634\">",
"      - Integral proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H530641\">",
"      - Peripheral proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7091|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/7/9334\" title=\"figure 1\">",
"      RBC membrane model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/48/13058\" title=\"figure 2\">",
"      Role of band 3 protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7091|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/59/26544\" title=\"picture 1\">",
"      Red cells in the spleen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=related_link\">",
"      Red blood cell mechanics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13353="The stages and natural history of HIV infection";
var content_f13_2_13353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The stages and natural history of HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13353/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13353/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13353/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/2/13353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human immunodeficiency virus (HIV) pandemic has spread to every country in the world and has infected 59 million persons worldwide, including 20 million who have already died [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An estimated 1.1 million persons in the United States have been infected with HIV; at the end of 2003, approximately 405,926 persons were living with AIDS. The number of reported cases in 2003 was essentially the same as the number in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/2\">",
"     2",
"    </a>",
"    ]. This trend follows a period of sharp decline in reported cases after the introduction of HAART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the original description in 1981 of an unusual cluster of cases of Pneumocystis carinii pneumonia and Kaposi's sarcoma in previously healthy homosexual males, substantial advances in our understanding of the acquired immune deficiency syndrome (AIDS) have been achieved. The identification of a cytopathic retrovirus in 1983 and development of a diagnostic serologic test for HIV-1 in 1985 have served as the basis for developing improvements in diagnosis.",
"   </p>",
"   <p>",
"    In addition, therapy was dramatically altered with the introduction of antiretroviral drugs in 1987 and revolutionized by combination treatment, known as highly active antiretroviral therapy (HAART), in 1996. In the three years following the introduction of HAART, mortality, AIDS, AIDS-defining diagnoses, and hospitalizations all decreased 60 to 80 percent. The EuroSIDA study, comparing this early HAART period to pre-HAART and later HAART (1998 to 2002) treatment periods, found a sustained decrease in mortality and progression to AIDS with ongoing HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite the absence of a cure, the natural history of the disease was radically changed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these advances, it is still useful to review the natural history of HIV infection without antiretroviral therapy and the classification of disease. Although modified from the initial case definition, the newer Centers for Disease Control and Prevention (CDC) classification system remains the cornerstone for diagnosing HIV and AIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGES OF HIV-1 INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 infection is divided into the following stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Viral transmission",
"     </li>",
"     <li>",
"      Primary HIV infection (also called acute HIV infection or acute seroconversion syndrome)",
"     </li>",
"     <li>",
"      Seroconversion",
"     </li>",
"     <li>",
"      Clinical latent period with or without persistent generalized lymphadenopathy (PGL)",
"     </li>",
"     <li>",
"      Early symptomatic HIV infection (previously known as \"AIDS-related complex\" or ARC and more recently referred to as Class B according to the 1993 CDC classification)",
"     </li>",
"     <li>",
"      AIDS (AIDS indicator condition according to the 1987 CDC criteria and revised 1993 CDC criteria that include a CD4 cell count below",
"      <span class=\"nowrap\">",
"       200/mm3",
"      </span>",
"      regardless of the presence or absence of symptoms)",
"     </li>",
"     <li>",
"      Advanced HIV infection characterized by a CD4 cell count below",
"      <span class=\"nowrap\">",
"       50/mm3",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VIRAL TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is usually acquired through sexual intercourse, exposure to contaminated blood, or perinatal transmission. The mode of acquiring HIV infection was undetermined in 4 percent of the cases originally reported to the CDC. A careful review of 32,497 cases, however, revealed that only 0.2 percent had no clearly defined risk factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mode of acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of the modes of transmission of HIV infection varies in different countries. In resource-limited areas, vaginal sex is responsible for 70 to 80 percent of AIDS cases and perinatal transmission and injection drug use (IDU) for 5 to 10 percent each [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, during the first 25 years of the epidemic in the United States, male-to-male sexual contact and IDU accounted for about one-half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative contribution of different routes of transmission has varied over time in the United States as reported by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated number of AIDS cases remained relatively stable, but the number of cases among men who have sex with men (MSM) and heterosexual adults and adolescents increased, while cases among injection drug users has declined [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heterosexual transmission was the most commonly reported mode of HIV acquisition among women.",
"     </li>",
"     <li>",
"      A follow-up survey for 2008 of 33 states found that 54 percent of new HIV diagnoses were among MSM, which represented an increase of 16.6 percent from 2001 to 2008; declines in case finding were seen concurrently in other risk groups (eg, high-risk heterosexuals and injection drug users) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients who have acquired HIV infection are unaware of their seropositive status. In the National HIV Behavioral Surveillance (NHBS) system, cross-sectional data are collected on populations at high risk for acquiring HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/10\">",
"     10",
"    </a>",
"    ]. In this ongoing study, MSM, injection drug users, and high risk heterosexuals are interviewed about their sexual and drug-use behaviors and are offered HIV testing. Of the 1767 MSM participants to date, 450 (25 percent) tested HIV-seropositive; 217 (48 percent) were unaware of their HIV infection. Compared with MSM who were HIV negative, MSM with unrecognized infections were less likely to have been tested during the preceding year because they were afraid of learning they had HIV (34 versus 68 percent in HIV-negative individuals).",
"   </p>",
"   <p>",
"    Minority populations are also at increased risk for HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ]. Rates of HIV infection in non-Hispanic black females were 19 times higher than rates among non-Hispanic white females [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/11\">",
"     11",
"    </a>",
"    ]. In the 2001-2006 CDC survey noted above, approximately twice as many HIV diagnoses were made in black MSM aged 13 to 24 years compared with white MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for HIV transmission include viral load, lack of circumcision, sexual risk, presence of ulcerative sexually transmitted diseases, nitrate inhalant use, and host and genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of viral load in relation to other potential risk factors for heterosexual transmission of HIV was examined in a prospective study of 415 Ugandan couples with discordant HIV serostatus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/13\">",
"     13",
"    </a>",
"    ]. Over a 30 month follow-up period, 90 patients seroconverted (21.7 percent). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficiency of transmission was approximately the same for female to male as for male to female.",
"     </li>",
"     <li>",
"      The mean viral load was significantly higher in those who transmitted HIV to their partner (90,254 compared with 38,029",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      Furthermore, there were no cases of transmission among the 51 subjects with HIV RNA levels less than 1500",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"     </li>",
"     <li>",
"      A dose response relationship of increased transmission with increased viral load was defined. In multivariate analysis, each log increment in the viral load was associated with a rate ratio of 2.45 for seroconversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of viral load is also underscored by mathematical models that suggest that a large proportion of HIV infections may be transmitted by individuals with primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/16\">",
"     16",
"    </a>",
"    ]. This is probably related to the high levels of viremia that are seen in the setting of acute infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link&amp;anchor=H957613#H957613\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\", section on 'HIV RNA detection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of sexually transmitted diseases also increases the risk of HIV acquisition as demonstrated in a study of 174 monogamous Ugandan couples with discordant HIV serostatus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The probability of transmission was approximately four times higher in patients with genital ulceration compared to those without. Multiple other studies have confirmed these results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sexual risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study that enrolled 3257 MSM in six US cities from 1995 to 1997, risk factors for HIV seroconversion included history of a large number of sexual partners, unprotected receptive anal sex with a partner with an unknown HIV serostatus, and use of nitrate inhalants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few studies documenting oral transmission of HIV infection; this could reflect low titers of infectious virus in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lack of circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of circumcision is associated with risk of HIV transmission in cohorts of heterosexual couples and MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genetic background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similarity of HLA-class-I alleles (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    ) between HIV discordant couples may affect the risk of transmission, by selecting for viral strains that are more likely to escape the immune containment of the seronegative partner. In a study of 125 initially serodiscordant couples with intracouple transmission, and 104 persistently serodiscordant couples, sharing of HLA-B alleles was associated with accelerated intracouple transmission of HIV after controlling for other variables (hazard ratio 2.23, 95% CI 1.52 to 3.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRIMARY HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic primary HIV infection occurs in many patients and has been reported in all major risk categories. The topic of primary HIV infection is discussed in detail elsewhere. Only issues related to primary infection and its impact on the natural history of HIV will be discussed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Symptoms and disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of symptoms and a prolonged illness (&gt;14 days) appears to correlate with more rapid progression to AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one study, for example, the risk of progression to an AIDS-defining diagnosis within three years following seroconversion was substantially higher in those with acute symptoms lasting more than 14 days than in those who were asymptomatic or had only mild symptoms (78 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Level of viremia at seroconversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following HIV seroconversion, there is marked variability in disease progression, in the absence of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a 1995 study of 62 MSM with documented HIV seroconversion, a plasma HIV RNA level greater than 1 x 10(5)",
"    <span class=\"nowrap\">",
"     Eq/mL",
"    </span>",
"    was the most powerful predictor of AIDS over time (OR 10.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/23\">",
"     23",
"    </a>",
"    ]. The persistence of detectable HIV RNA in plasma after primary HIV infection was associated with the development of AIDS and significant CD4 T cell count declines. In a prospective study of 218 female sex workers in Kenya with a median duration of follow-up of 4.6 years, higher set point viremia, lower early CD4 T cell counts, and symptomatic primary HIV infection predicted faster progression to death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After approximately six months of infection, plasma viremia reaches a steady state level; cytotoxic CD8 T cells play a critical role in achieving that equilibrium and preventing further decline in the CD4 cell compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a prospective study of 33 patients with primary HIV-1 infection, those with higher frequencies of Env-specific memory CTLs had median levels of plasma HIV-1 RNA only about one-third that of patients with lower frequencies and had a lower likelihood of progression to a CD4 cell count below",
"    <span class=\"nowrap\">",
"     300/mm3",
"    </span>",
"    at 18 months (20 versus 56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The topic of primary HIV infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SEROCONVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients seroconvert to positive HIV serology within 4 to 10 weeks after exposure using newer diagnostic tests, and &ge;95 percent seroconvert within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The median time from exposure to positive serology in one study was 63 days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small proportion of seroconverters demonstrate significant immune responses and virologic control early in infection. In an analysis of 2176 patients with documented HIV seroconversion, 145 patients (7 percent) spontaneously controlled viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/31\">",
"     31",
"    </a>",
"    ]. Women, and those without symptoms at seroconversion, were more likely to achieve a non-detectable HIV RNA. Such virologic control may have a profound effect on the natural history of HIV infection. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Long-term nonprogressors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL LATENT PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The period of early HIV disease extends from seroconversion to six months following HIV transmission. During the period of asymptomatic infection, patients generally have no findings on physical examination except for possible lymphadenopathy. \"Persistent generalized lymphadenopathy\" (PGL) is defined as enlarged lymph nodes involving at least two noncontiguous sites other than inguinal nodes. Studies of the lymph nodes at this stage reveal high concentrations of extracellular HIV on the follicular dendritic cell processes within germinal centers and intracellular HIV predominantly in its latent form [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lymphoid tissue serves as the major reservoir for HIV. The follicular dendritic cells in lymphoid tissue filter and trap free virus and infected CD4 T cells. The viral burden in peripheral blood mononuclear cells is relatively low at this time. The lymph node architecture is disrupted and more HIV is released peripherally into the bloodstream as the disease progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Viral dynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virologic studies in patients with asymptomatic HIV infection show high rates of HIV replication and destruction of an average of 10(9) CD4 cells daily [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Cell death and replacement are in near balance during this phase of the illness; thus, a relatively steady state of cell counts and viral load is achieved despite remarkably high turnover rates of HIV and CD4 cells. As an example, the HIV RNA levels are usually stable over time with only rare changes exceeding 1 log [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The half-life of HIV in serum is approximately 1.2 days, about 24 hours intracellularly, and about 6 hours as extracellular virus. About 30 percent of the total body viral burden is turned over daily. Furthermore, 6 to 7 percent of the total CD4 cells turnover each day, and the entire supply of CD4 cells turns over every 15 days. The implication of these observations is that \"AIDS is primarily a consequence of continuous, high-level replication of HIV-1, leading to virus and immune-mediated killing of CD4 lymphocytes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This \"set point\" in the viral load and the CD4 count correlates with prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Viral load is the most important predictor of progressive disease in early stages of HIV infection while the CD4 count is an important prognosticator in late stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     CD4 T cell dynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies show considerable variation between patients in CD4 cell count and viral burden during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/39\">",
"     39",
"    </a>",
"    ]. The viral load stabilizes at six months and often remains at the same level or increases slowly (0.15 percent per week in one series) for a few years in the absence of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based studies of the natural history of HIV infection in MSM show that the mean CD4 count prior to seroconversion is approximately",
"    <span class=\"nowrap\">",
"     1000/mm3.",
"    </span>",
"    The count decreases to a mean of",
"    <span class=\"nowrap\">",
"     780/mm3",
"    </span>",
"    at six months post-seroconversion and to",
"    <span class=\"nowrap\">",
"     670/mm3",
"    </span>",
"    at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/40\">",
"     40",
"    </a>",
"    ]. However, some patients have a substantially lower CD4 count at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. A study of 40 recent seroconverters followed prospectively without treatment showed that 11 (28 percent) had a CD4 count of &lt;350",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    by week 36 and 20 (50 percent) reached this CD4 threshold by 72 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rapid decline in CD4 cells in the early stages of HIV infection may reflect destruction of CD4 cells or a shift of CD4 cells from the peripheral blood to lymphatic tissue. After one year, the rate of CD4 cell decline averages about",
"    <span class=\"nowrap\">",
"     50/mm3",
"    </span>",
"    per year, with a range of 30 to",
"    <span class=\"nowrap\">",
"     90/mm3",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/36,40,43-46\">",
"     36,40,43-46",
"    </a>",
"    ]. As expected, the rate of CD4 cell decline correlates with the viral burden, which averaged a decrease of 4 percent per log10",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    per year in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of patients has sustained high levels of CD4 cells. The term \"chronic nonprogressor\" is sometimes used in reference to these patients. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Long-term nonprogressors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EARLY SYMPTOMATIC HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stage of early symptomatic HIV infection is also called \"Class B\" according to the CDC 1993 classification system and was formerly called \"AIDS-related complex\". Examples of Class B conditions are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef54622 \" href=\"UTD.htm?13/8/13451\">",
"     table 1",
"    </a>",
"    ). Although these diseases occur in association with many disorders, they are more frequent and more severe when associated with HIV infection. The B conditions are",
"    <strong>",
"     not",
"    </strong>",
"    AIDS-indicator conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of AIDS has evolved since the beginning of the epidemic.",
"   </p>",
"   <p>",
"    The 1987 definition of AIDS included conditions indicative of severe immunosuppression, especially defective cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/48\">",
"     48",
"    </a>",
"    ]. The subsequent revised CDC classification has three ranges of CD4 cell counts and uses a matrix of nine mutually exclusive categories (",
"    <a class=\"graphic graphic_table graphicRef69767 \" href=\"UTD.htm?5/33/5660\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 1993 definition of AIDS includes all of the AIDS-indicator diseases in the 1987 version with three additions: recurrent bacterial pneumonia; invasive cervical cancer; and pulmonary tuberculosis (",
"    <a class=\"graphic graphic_table graphicRef71569 \" href=\"UTD.htm?18/59/19388\">",
"     table 3",
"    </a>",
"    ). The most substantive change in the classification was the inclusion of all patients with a CD4 cell count below",
"    <span class=\"nowrap\">",
"     200/mm3",
"    </span>",
"    regardless of the presence or absence of symptoms.",
"   </p>",
"   <p>",
"    Using data from the Multicenter AIDS Cohort Study, the median CD4 count at the time of an AIDS-defining complication was 67",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/49\">",
"     49",
"    </a>",
"    ]. However, approximately 10 percent of patients develop an AIDS-defining diagnosis with a CD4 count above",
"    <span class=\"nowrap\">",
"     200/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    The median time from the onset of severe immunosuppression (defined as a CD4 cell count below",
"    <span class=\"nowrap\">",
"     200/mm3)",
"    </span>",
"    to an AIDS-defining diagnosis (1987 criteria) is 12 to 18 months in persons not receiving antiretroviral treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with depletion of CD4 T cells, humoral immunity wanes over time. B cells exhibit increased expression of markers of activation and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, in advanced HIV infection, B cells undergo terminal differentiation leading to increased immunoglobulin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/52\">",
"     52",
"    </a>",
"    ]. This may lead to a polyclonal hypergammaglobulinemia; however, many of these antibodies are non-specific. This may explain the paradox between high circulating levels of immunoglobulins and an increased risk of bacterial infections (eg, recurrent pneumonia) that occurs in late-stage AIDS. Humoral immunity generally improves dramatically after the initiation of antiretroviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Conditions that define an AIDS diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the HAART era, the CDC reported 71,704 new cases in the 1997 fiscal year. The following was the rank order of first AIDS-defining conditions in the CDC",
"    <span class=\"nowrap\">",
"     Adult/Adolescent",
"    </span>",
"    Spectrum of HIV Disease Sentinel Surveillance Project [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      P. carinii pneumonia &mdash; 42.6 percent",
"     </li>",
"     <li>",
"      Esophageal candidiasis - 15.0 percent",
"     </li>",
"     <li>",
"      Wasting &mdash; 10.7 percent",
"     </li>",
"     <li>",
"      Kaposi's sarcoma &mdash; 10.7 percent",
"     </li>",
"     <li>",
"      Disseminated M. avium infection &mdash; 4.8 percent",
"     </li>",
"     <li>",
"      Tuberculosis &mdash; 4.5 percent",
"     </li>",
"     <li>",
"      Cytomegalovirus disease &mdash; 3.7 percent",
"     </li>",
"     <li>",
"      HIV-associated dementia &mdash; 3.6 percent",
"     </li>",
"     <li>",
"      Recurrent bacterial pneumonia &mdash; 3.0 percent",
"     </li>",
"     <li>",
"      Toxoplasmosis &mdash; 2.6 percent",
"     </li>",
"     <li>",
"      Immunoblastic lymphoma - 1.9 percent",
"     </li>",
"     <li>",
"      Chronic cryptosporidiosis - 1.5 percent",
"     </li>",
"     <li>",
"      Burkitt lymphoma - 1.5 percent",
"     </li>",
"     <li>",
"      Disseminated histoplasmosis - 1.0 percent",
"     </li>",
"     <li>",
"      Invasive cervical cancer - 0.9 percent",
"     </li>",
"     <li>",
"      Chronic Herpes simplex &mdash; 0.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Advanced HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HIV infection have a CD4 cell count below",
"    <span class=\"nowrap\">",
"     50/mm3.",
"    </span>",
"    Their median survival is 12 to 18 months in the absence of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Virtually all patients who die of HIV-related complications have CD4 cell counts in this range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LONG-TERM NONPROGRESSORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients exhibit remarkable clinical stability and remain asymptomatic over many years without antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/45,57-59\">",
"     45,57-59",
"    </a>",
"    ]. These patients are called \"long-term nonprogressors,\" which was historically defined as HIV infection for at least 10 years, no antiretroviral agents, lack of symptoms, CD4 count above",
"    <span class=\"nowrap\">",
"     500/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Large longitudinal studies show that 4 to 7 percent of HIV-infected patients satisfy these criteria and this reflects to a large extent a robust cytotoxic T cell response and preservation of lymph node architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the experience in the MACS data suggests that 13 percent of MSM infected at a young age will remain asymptomatic for more than 20 years without antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/33\">",
"     33",
"    </a>",
"    ]. Similar results have been noted in persons with hemophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/34\">",
"     34",
"    </a>",
"    ]. The main correlate with delayed progression is low viral burden (eg, 1000 to 10,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    that probably reflects an effective immunologic response with HIV-specific CD4 T cells early in the course of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ELITE CONTROLLERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Elite controllers\" are HIV-seropositive individuals who have no evidence of viremia, as measured by standard assays (either &lt;50 or &lt;75",
"    <span class=\"nowrap\">",
"     copies/mL),",
"    </span>",
"    and maintain high CD4 cell counts. These patients represent a small minority of HIV-infected individuals",
"    <span class=\"nowrap\">",
"     (1/300",
"    </span>",
"    patients) and the mechanisms that lead to spontaneous virologic control without treatment are unknown. Several factors may be responsible for spontaneous virologic control among individual elite controllers including infection with a defective HIV variant or host genetic polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/57,59\">",
"     57,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In elite controllers, viral load suppression has been observed to be comparable to that seen in patients who are taking potent combination antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The median viral load in two cohorts of such patients was 2",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    although there were fluctuations over time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/60-62,64\">",
"     60-62,64",
"    </a>",
"    ]. Disease progression with CD4 cell count decline is unusual, but one report noted this in up to 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/65\">",
"     65",
"    </a>",
"    ]; this has not been noted in any of the 63 elite progressors followed at the NIH for a median of 19 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/61\">",
"     61",
"    </a>",
"    ]. The HLA class I alleles that are most consistently noted with elite control of HIV are B*57 and Cwo602 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/60,64\">",
"     60,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated cellular and humoral immune responses and host genetics in 64 elite controllers, 50 persons with low levels of detectable viremia (&lt;2000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    \"viremic controllers\"), and patients with progressive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13353/abstract/66\">",
"     66",
"    </a>",
"    ]. This showed that HIV gag protein was preferentially targeted by CD8 T-cell responses in elite and viremic controllers compared with patients with progressive infection. The elite controller group also had a higher frequency of HIV-specific CD4 and CD8 T-cells producing interferon gamma and interleukin-2 and a paucity of broadly cross-reactive neutralizing antibodies compared with the other two groups.",
"   </p>",
"   <p>",
"    Further studies, including viral and host genetic analyses, are underway in the International HIV Controllers Study that seeks to enroll 1000 elite controllers and 1000 viremic controllers. More information regarding this study is available at",
"    <a class=\"external\" href=\"file://www.hivcontrollers.org/\">",
"     www.hivcontrollers.org",
"    </a>",
"    . Other HIV controller cohorts include those based in Bethesda, Paris, Baltimore, San Francisco, Amsterdam, and Madrid. &nbsp;More information on these studies is available through the National Institutes of Health (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=long-term+non+progressors&amp;fund=0\">",
"     file://clinicaltrials.gov/ct2/results?term=long-term+non+progressors&amp;fund=0",
"    </a>",
"    ), the AIDS Research Alliance (310-358-2429), and within major cities in the United States (eg, San Francisco;",
"    <a class=\"external\" href=\"file://ari.ucsf.edu/programs/elite.aspx\">",
"     file://ari.ucsf.edu/programs/elite.aspx",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"       \"Patient information: Tests to monitor HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-1 infection is divided into stages of primary infection with seroconversion, clinical latency, early symptomatic disease, and AIDS. The mode of acquisition is mainly through heterosexual transmission in developing countries; in the United States, men who have sex with men (MSM) and persons exposed through heterosexual contact account for the majority of",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      diagnoses. Risk factors for transmission include high plasma HIV viral load and presence of ulcerative genital sexually transmitted diseases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Viral transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic primary HIV infection occurs in many patients and has been reported in all major risk categories. The presence of symptoms and a prolonged illness correlates with more rapid progression to AIDS. The period of early HIV disease extends from seroconversion to six months following HIV transmission. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the period of asymptomatic infection, patients generally have no findings on physical examination except for lymphadenopathy. Despite the lack of symptoms, high rates of HIV replication and CD4 T cell destruction may be occurring. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical latent period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stage of early symptomatic HIV infection is called \"Class B\" according to the CDC 1993 classification system and was formerly called \"AIDS-related complex\". The most substantive change in the classification system was the inclusion of all patients with a CD4 cell count below",
"      <span class=\"nowrap\">",
"       200/mm3",
"      </span>",
"      as having AIDS, regardless of the presence or absence of symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Early symptomatic HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     UNAIDS. Report on the Global AIDS epidemic, 2004. Bangkok, Thailand 2004. www.unaids.org (Accessed on May 31, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/2\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/3\">",
"      Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/4\">",
"      Sterne JA, Hern&aacute;n MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/5\">",
"      Adler MW. ABC of Aids: Development of the epidemic. BMJ 2001; 322:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/6\">",
"      Cohen MS, Hellmann N, Levy JA, et al. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008; 118:1244.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control, Divisions of HIV/AIDS Prevention, 2005. www.cdc.gov/hiv/stats.htm (Accessed on May 31, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Trends in HIV/AIDS diagnoses among men who have sex with men--33 states, 2001-2006. MMWR Morb Mortal Wkly Rep 2008; 57:681.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV Surveillance Report 2008. [Published June 2010] file://www.cdc.gov/hiv/topics/surveillance/resources/reports.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men--five U.S. cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep 2005; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Diagnoses of HIV/AIDS--32 States, 2000-2003. MMWR Morb Mortal Wkly Rep 2004; 53:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/12\">",
"      Hightow LB, MacDonald PD, Pilcher CD, et al. The unexpected movement of the HIV epidemic in the Southeastern United States: transmission among college students. J Acquir Immune Defic Syndr 2005; 38:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/13\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/14\">",
"      Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/15\">",
"      Dorak MT, Tang J, Penman-Aguilar A, et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/16\">",
"      Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/17\">",
"      Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/18\">",
"      Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005; 39:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/19\">",
"      Malamud D, Wahl SM. The mouth: a gateway or a trap for HIV? AIDS 2010; 24:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/20\">",
"      Baeten JM, Donnell D, Kapiga SH, et al. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS 2010; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/21\">",
"      Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/22\">",
"      Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993; 168:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/23\">",
"      Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/24\">",
"      Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/25\">",
"      Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A 1997; 94:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/26\">",
"      Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/27\">",
"      Coutl&eacute;e F, Olivier C, Cassol S, et al. Absence of prolonged immunosilent infection with human immunodeficiency virus in individuals with high-risk behaviors. Am J Med 1994; 96:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/28\">",
"      Simmonds P, Lainson FA, Cuthbert R, et al. HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort. Br Med J (Clin Res Ed) 1988; 296:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/29\">",
"      Sheppard HW, Busch MP, Louie PH, et al. HIV-1 PCR and isolation in seroconverting and seronegative homosexual men: absence of long-term immunosilent infection. J Acquir Immune Defic Syndr 1993; 6:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/30\">",
"      Alcabes P, Mu&ntilde;oz A, Vlahov D, Friedland GH. Incubation period of human immunodeficiency virus. Epidemiol Rev 1993; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/31\">",
"      Madec Y, Boufassa F, Porter K, et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005; 19:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/32\">",
"      Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/33\">",
"      Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/34\">",
"      Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/35\">",
"      Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/36\">",
"      Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/37\">",
"      Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/38\">",
"      Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/39\">",
"      Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/40\">",
"      Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/41\">",
"      Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368:489.",
"     </a>",
"    </li>",
"    <li>",
"     Hogan C, DeGruttola V, Daar E, et al. A finite course of ART during early HIV-1 infection modestly delays need for subsequent ART initiation: ACTG A5217, the SETPOINT Study. 2010 Conference on Retroviruses and Opportunisitc Infections, Abstr. #134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/43\">",
"      Galai N, Vlahov D, Margolick JB, et al. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/44\">",
"      Lang W, Perkins H, Anderson RE, et al. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/45\">",
"      Margolick JB, Mu&ntilde;oz A, Vlahov D, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA 1992; 267:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/46\">",
"      Hughes MD, Stein DS, Gundacker HM, et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/47\">",
"      Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/48\">",
"      Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36 Suppl 1:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/49\">",
"      Taylor JM, Sy JP, Visscher B, Giorgi JV. CD4+ T-cell number at the time of acquired immunodeficiency syndrome. Am J Epidemiol 1995; 141:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/50\">",
"      Karon JM, Buehler JW, Byers RH, et al. Projections of the number of persons diagnosed with AIDS and the number of immunosuppressed HIV-infected persons--United States, 1992-1994. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/51\">",
"      Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004; 200:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/52\">",
"      Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001; 98:10362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/53\">",
"      Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/54\">",
"      Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991; 115:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/55\">",
"      Phillips AN, Elford J, Sabin C, et al. Immunodeficiency and the risk of death in HIV infection. JAMA 1992; 268:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/56\">",
"      Easterbrook PJ, Emami J, Moyle G, Gazzard BG. Progressive CD4 cell depletion and death in zidovudine-treated patients. J Acquir Immune Defic Syndr 1993; 6:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/57\">",
"      Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/58\">",
"      Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/59\">",
"      Mu&ntilde;oz A, Kirby AJ, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/60\">",
"      Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 2010; 304:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/61\">",
"      Klein MR, Miedema F. Long-term survivors of HIV-1 infection. Trends Microbiol 1995; 3:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/62\">",
"      Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/63\">",
"      Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis 2008; 47:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/64\">",
"      Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/65\">",
"      Sedaghat AR, Rastegar DA, O'Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009; 49:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13353/abstract/66\">",
"      Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3724 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13353=[""].join("\n");
var outline_f13_2_13353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGES OF HIV-1 INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VIRAL TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mode of acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Viral load",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sexual risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lack of circumcision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genetic background",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRIMARY HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Symptoms and disease progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Level of viremia at seroconversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SEROCONVERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL LATENT PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Viral dynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CD4 T cell dynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EARLY SYMPTOMATIC HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Conditions that define an AIDS diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Advanced HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LONG-TERM NONPROGRESSORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ELITE CONTROLLERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3724\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3724|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/8/13451\" title=\"table 1\">",
"      Early symptomatic HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/33/5660\" title=\"table 2\">",
"      AIDS case definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/59/19388\" title=\"table 3\">",
"      Indicator conditions in AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=related_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13354="Septic shock: Ongoing management after resuscitation in children";
var content_f13_2_13354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Septic shock: Ongoing management after resuscitation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Scott L Weiss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Wendy J Pomerantz, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/2/13354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/2/13354/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/2/13354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18272002\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome complicating severe infection that is characterized by systemic inflammation, immune dysregulation, microcirculatory derangements, and end-organ dysfunction. There is a continuity of severity ranging from sepsis to severe sepsis and septic shock. Severe sepsis and septic shock are characterized by dysfunction of &ge;2 organ systems and cardiovascular dysfunction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/1\">",
"     1",
"    </a>",
"    ]. With increased attention to rapid recognition, aggressive fluid administration, and early administration of vasoactive agents and antibiotics, pediatric mortality from severe sepsis and septic shock has decreased markedly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of severe sepsis and septic shock in children after the first hour of resuscitation is reviewed here. The rapid recognition and initial resuscitation of pediatric septic shock and the definitions, epidemiology, and clinical manifestations of sepsis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1585416\">",
"    <span class=\"h1\">",
"     RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key interventions in the initial resuscitation of children from septic shock are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270326\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeated, frequent assessment of the patient in septic shock is essential. In children who have responded to therapy with resolution of hypotension, ongoing monitoring, antimicrobial therapy, and optimal respiratory support are essential.",
"   </p>",
"   <p>",
"    In patients with fluid-refractory hypotension, ongoing aggressive resuscitation should continue after the initial resuscitation of pediatric septic shock according to the principles of goal-directed therapy, (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H6411955#H6411955\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Physiologic indicators and target goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whenever possible, children requiring resuscitation for septic shock should receive ongoing management by a pediatric critical care specialist or pediatrician with similar expertise in a pediatric intensive care unit.",
"   </p>",
"   <p>",
"    Priorities for continued management of children with septic shock include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control the infection by identifying the optimal choice of antimicrobial therapy based upon culture results and by ensuring that the source of infection is controlled",
"     </li>",
"     <li>",
"      Ongoing monitoring of respiratory status and provision of optimal respiratory support",
"     </li>",
"     <li>",
"      Ongoing monitoring of tissue perfusion and blood pressure",
"     </li>",
"     <li>",
"      Correction of electrolyte and metabolic derangements (eg, hypoglycemia, hypocalcemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the subpopulation of children with fluid-refractory septic shock requiring continued vasopressor support, additional priorities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement of invasive monitoring devices (eg, central venous catheter, arterial line, bladder catheter) to accurately assess blood pressure and to deliver vasopressor infusions safely",
"     </li>",
"     <li>",
"      Continued fluid resuscitation and vasopressor delivery targeted to principles of goal-directed therapy",
"     </li>",
"     <li>",
"      Administration of blood products, when needed, to treat anemia and coagulopathy",
"     </li>",
"     <li>",
"      Treatment of adrenal insufficiency and evaluation of other potential underlying causes (eg, hypothyroidism)",
"     </li>",
"     <li>",
"      Provision of advanced therapies in patients who do not respond to conventional therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If physiologic goals have been achieved, indicating that perfusion is improved, the patient should continue to receive supportive treatment and careful monitoring. The goals of treatment include achieving a normal blood pressure, improved mental status and good perfusion for the patient who is hypotensive. For children with compensated shock and normal blood pressures, therapeutic endpoints based upon noninvasive indicators are reasonable targets, but may be unreliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H6411955#H6411955\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Physiologic indicators and target goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270333\">",
"    <span class=\"h2\">",
"     Eradicate infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt identification and treatment of the source of infection are essential to successful management of septic shock and constitute critical interventions that can reverse septic shock. In contrast, other therapies (eg, fluid administration, vasoactive drug infusion, or mechanical ventilation) are purely supportive in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A careful history and physical examination may yield clues to the source of sepsis and help guide subsequent microbiologic evaluation (",
"    <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"     table 1",
"    </a>",
"    ). Gram stain of suspicious fluids may give early clues to the etiology of infection while cultures are incubating. In addition to cultures of specific sites, blood should be drawn and inoculated into standard blood culture media. Blood cultures should be incubated both aerobically and anaerobically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eradication of the inciting infection is essential for the successful treatment of septic shock. This includes prompt administration of antimicrobial therapy and source control. Initial antimicrobial therapy should provide broad spectrum coverage tailored to host factors, such as age and underlying medical conditions, and be administered as soon as possible after presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Source control (physical measures undertaken to eradicate a focus of infection, to eliminate ongoing microbial contamination, and to render a site inhospitable to microbial growth and invasion) should be undertaken when possible because localized foci of infection (ie, abscess) may not respond to antibiotics alone (",
"    <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"     table 1",
"    </a>",
"    ). As examples, potentially infected foreign bodies should be removed and abscesses, infected fluid collections, or tissues should be percutaneously or surgically drained and d&eacute;brided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H22#H22\">",
"     \"Necrotizing soft tissue infections\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627387\">",
"    <span class=\"h2\">",
"     Continue respiratory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygenation should be monitored using continuous pulse oximetry (SpO2). Patients should continue to receive supplemental oxygen to maintain oxygen saturation at 100 percent (patients with continued shock) or 97 percent (patients with restored perfusion and blood pressure).",
"   </p>",
"   <p>",
"    In patients with continued shock, endotracheal intubation should be performed if not already accomplished. Mechanical ventilation should be performed with the following goals in mind [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keep plateau pressure &le;30 cmH",
"      <sub>",
"       2",
"      </sub>",
"      O",
"     </li>",
"     <li>",
"      Keep tidal volume under 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      ideal body weight. Tidal volume may need to be decreased as low as 4 to 6",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      in patients with very low lung compliance using lung protective ventilation strategies to achieve a plateau pressure &le;30 cmH",
"      <sub>",
"       2",
"      </sub>",
"      O [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maintain arterial pH between 7.30 and 7.45",
"     </li>",
"     <li>",
"      Titrate fraction of inspired oxygen (FiO2) and positive end-expiratory pressure to maintain arterial oxygen concentration (PaO",
"      <sub>",
"       2)",
"      </sub>",
"      between 60 and 80 mmHg (8 to 10.7 kPa) or pulse oximetry 90 to 97 percent in patients with hypoxia who require FiO2 &ge;50 percent",
"     </li>",
"     <li>",
"      Maintain hemoglobin &ge;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H18270354\">",
"       'Blood transfusion'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270340\">",
"    <span class=\"h2\">",
"     Ongoing and invasive monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During initial management, monitoring of tissue perfusion using physiologic indicators and target goals continues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H6411955#H6411955\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Physiologic indicators and target goals'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the clinician should determine the need for invasive monitoring via intraarterial and central venous cannulas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intraarterial cannula placement",
"      </strong>",
"      &ndash; Although noninvasive blood pressure measurement is acceptable in patients who have markedly improved or had total reversal of septic shock, automated blood pressures overestimate systolic blood pressure relative to intraarterial or Doppler ultrasound measurements in hypotensive children and underestimate systolic blood pressure among hypertension patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/15\">",
"       15",
"      </a>",
"      ]. Thus, insertion of an intraarterial catheter is suggested if blood pressure is labile or if restoration of arterial perfusion pressures is expected to be a protracted process. However, efforts to obtain intraarterial access should",
"      <strong>",
"       not",
"      </strong>",
"      interfere with the resuscitation of septic shock. Procedures for obtaining intraarterial access in children are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=see_link&amp;anchor=H10#H10\">",
"       \"Arterial puncture and cannulation in children\", section on 'Arterial cannulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central venous access",
"      </strong>",
"      &ndash; Central venous access is indicated in patients who require infusion of vasoactive drugs to maintain adequate tissue perfusion, and in patients with catecholamine-resistant septic shock who warrant monitoring of central venous pressures (CVP) and central venous oxygen saturation (ScvO2). In the absence of an elevated intraabdominal pressure, the correlation between femoral vein pressure and CVP is good, though absolute values may differ slightly [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Changes in central venous oxygen saturation (ScvO2), which provides reliable information regarding tissue oxygenation should also be frequently monitored [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/18\">",
"       18",
"      </a>",
"      ]. If direct measure of ScvO2 is not available, limited evidence suggests that a capillary refill time &le;2 seconds is associated with a ScvO2 &ge;70 percent. However, capillary refill time can be brisk despite significant hemodynamic derangement in children with septic shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H4#H4\">",
"       \"Initial management of shock in children\", section on 'Physiologic indicators and target goals'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270347\">",
"    <span class=\"h2\">",
"     Continue fluid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for aggressive administration of fluids to optimize tissue perfusion and to achieve physiologic goals typically continues beyond the first hour of care in children with septic shock. In patients with persistent poor perfusion or hypotension, boluses of fluids should continue until the central venous pressure is 8 to 12 cmH",
"    <sub>",
"     2",
"    </sub>",
"    O (12 to15 cmH",
"    <sub>",
"     2",
"    </sub>",
"    O in mechanically ventilated patients) or evidence of cardiac insufficiency (eg, pulmonary edema, enlarged heart) occurs. The volume per bolus and types of fluid are as for the resuscitation period (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ). Fluid input and output should be carefully monitored on an hourly basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450206#H19450206\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Intravenous fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18272996\">",
"    <span class=\"h3\">",
"     Fluid overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial edema is common in sepsis due to increased vascular permeability. In patients with clinical findings of significant fluid overload (eg, pitting edema, anasarca, or pulmonary edema), early initiation of diuretic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    ) may be appropriate in patients with hypoxia and pulmonary edema",
"    <strong>",
"     after",
"    </strong>",
"    a period of 12 to 24 hours of sustained hemodynamic stability off vasoactive infusions. Patients in whom urine output remains insufficient may warrant renal replacement therapy (eg, continuous veno-venous hemofiltration or intermittent hemodialysis). Observational studies in critically ill children, including children with sepsis who received renal replacement therapies, indicate that more than 10 percent fluid overload is associated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, the evidence is not sufficient to determine whether or not fluid overload has an independent deleterious effect on survival. Nonsurvivors may have had more severe septic shock and therefore, required greater amount of fluid and were more likely to develop renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270354\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin is the primary determinant of blood oxygen carrying capacity and, therefore, of tissue oxygen delivery. Thus, maintaining adequate hemoglobin levels is a critical aspect of managing children with septic shock. We suggest a hemoglobin goal of 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (equivalent to 30 percent hematocrit) as a target to maintain with blood transfusion during resuscitation and ongoing management of children with septic shock (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/12\">",
"     12",
"    </a>",
"    ]. The safety of tolerating a lower hemoglobin in unstable patients with vasopressor-dependent hypotension from sepsis has not been studied.",
"   </p>",
"   <p>",
"    Once shock has resolved, a lower hematocrit threshold for blood transfusion is likely to be safe. As an example, in a multicenter unblinded trial of 137 stabilized children with sepsis (mean systemic arterial pressure was not below two standard deviations of normal for age and cardiovascular support was not increased for at least two hours before enrollment) that compared restrictive transfusion (transfusion for hemoglobin &lt;7.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    with liberal transfusion (transfusion for hemoglobin &lt;9.5",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    no clinically significant differences were found for the occurrence of new or progressive multiple organ dysfunction syndrome (18.8 versus 19.1 percent), PICU length of stay (13 days in both groups), or PICU mortality (7 versus 3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/21\">",
"     21",
"    </a>",
"    ]. However, two additional patients died in the restrictive transfusion group after discharge from the pediatric intensive care unit.",
"   </p>",
"   <p>",
"    Given that a restrictive approach to transfusion in patients with sepsis does not appear inferior to more liberal management in stable patients recovering from septic shock, we typically use a hemoglobin of 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    as the threshold for blood transfusion in",
"    <strong>",
"     stable",
"    </strong>",
"    patients recovering from septic shock instead of 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    which we suggest for patients with ongoing hemodynamic instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1584851\">",
"    <span class=\"h2\">",
"     Treat disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with septic shock frequently have disseminated intravascular coagulopathy that may warrant treatment. Thus, baseline measures of clotting status should be routinely obtained in children with septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19451427#H19451427\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Suggestive laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no trials to study the efficacy of platelet, fresh frozen plasma (FFP), or cryoprecipitate transfusions in children with sepsis and DIC. Nevertheless, the use of these agents seems rational in patients with significant bleeding (melena, or prolonged bleeding from venipuncture sites) due to thrombocytopenia and clotting factor consumption or significant risk of bleeding (eg, pre- or postoperative patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H30#H30\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of replacement therapy is to reduce or stop significant bleeding. Although replacement therapy should not be used to normalize laboratory tests (which often is impossible), a reasonable guide for the judicious use of blood components in the setting of significant bleeding includes maintaining platelet counts &gt;50,000 per mm&sup3; and fibrinogen concentration &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H30#H30\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Replacement therapy'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Clotting factors can be replaced by either FFP or cryoprecipitate. FFP provides both procoagulant and anticoagulant proteins and is administered every 12 to 24 hours at a dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per infusion. Cryoprecipitate has higher concentrations of factor VIII and fibrinogen, and can be used to correct hypofibrinogenemia. It is administered every six hours as needed at a dose of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per infusion. Platelet transfusions are administered with a goal of maintaining the platelet counts &gt;50,000 per mm&sup3;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link&amp;anchor=H30#H30\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although initial observational studies indicated that children with sepsis frequently have low circulating levels of",
"    <strong>",
"     activated",
"    </strong>",
"    protein C, administration of recombinant human",
"    <strong>",
"     activated",
"    </strong>",
"    protein C (drotrecogin alfa) has shown no benefit and may be harmful. As an example, in a multicenter randomized trial comparing drotrecogin alpha with placebo for the treatment of children with severe sepsis, interim analysis demonstrated no benefit for treatment with drotrecogin alpha and an increased incidence of central nervous system bleeding, particularly in those younger than 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, this trial was discontinued. A systematic review that included this trial concluded that recombinant human",
"    <strong>",
"     activated",
"    </strong>",
"    protein C should not be used for any children or for adults who are not severely ill [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/23\">",
"     23",
"    </a>",
"    ]. In October 2011, drotrecogin alpha was voluntarily removed from the worldwide market by Eli Lilly due to a negative second trial in adults with severe septic shock.",
"   </p>",
"   <p>",
"    Observational and dose finding studies of protein C",
"    <strong>",
"     concentrate",
"    </strong>",
"    in selected children with severe meningococcal septic shock, and purpura fulminans have shown potential promise. Protein C",
"    <strong>",
"     concentrate",
"    </strong>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    biologically active on administration (requires conversion to",
"    <strong>",
"     activated",
"    </strong>",
"    protein C by thrombin or thrombin bound to endothelial thrombomodulin) and is used mainly in patients with severe congenital protein C deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Protein C concentrate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270361\">",
"    <span class=\"h2\">",
"     Manage glucose abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia remains a concern during the initial management phase of septic shock. Children have limited glycogen stores and may develop profound hypoglycemia during periods of stress. Thus, blood glucose should be monitored frequently upon admission and at least every six hours while the patient is unstable and corrected (",
"    <a class=\"graphic graphic_table graphicRef83485 \" href=\"UTD.htm?31/43/32446\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H2984154#H2984154\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Treat hypoglycemia and hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once tissue perfusion is restored and shock is resolved, children should receive intravenous fluid that contains dextrose sufficient to maintain euglycemia. This therapy typically consists of 5 to 10 percent dextrose in electrolyte solution appropriate to the patient&rsquo;s ongoing sodium and potassium requirements. The glucose dose is determined by age: 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (neonates), 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (children), 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute (adolescents) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia is commonly present in children with septic shock. Data regarding exogenous insulin as a means to maintain euglycemia in these patients is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one small observational study of 57 children with septic shock, children who died had higher peak serum glucose levels than survivors (262 versus 168",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one small series of 16 children with meningococcal sepsis or septic shock, hyperglycemia reflected hypoinsulinemia rather than insulin resistance in those patients with septic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 700 critically ill infants and children admitted to a pediatric intensive care unit (PICU) that compared conventional versus intensive control of serum glucose, duration of PICU stay was shortest in the intensive versus conventional treatment group (5.5 versus 6.2 days). However, hypoglycemia (defined as blood glucose &le;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.22",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      was more common in children receiving intensive glucose control (25 versus 1 percent, respectively). Nine (3 percent) patients died in the intensively treated group versus 20 (6 percent) in the conventional group (p = 0.038) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/27\">",
"       27",
"      </a>",
"      ]. At a median of four years of follow-up, children who had been treated with tight glycemic control during their ICU admission did not have a worse measure of intelligence than those who had received usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 980 children (0 to 36 months of age), undergoing surgery with cardiopulmonary bypass randomized to either tight glycemic control (with the use of an insulin-dosing algorithm) targeting a blood glucose level of 80 to 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.44 to 6.12",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or standard care in the cardiac intensive care unit, no difference was found in the rate of health care-associated infections (8.6 versus 9.9 per 1000 patient-days) or other secondary outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/29\">",
"       29",
"      </a>",
"      ]. This study used continuous glucose monitoring to guide the frequency of blood glucose measurement and to detect impending hypoglycemia, with only 3 percent of the patients in the tight glycemic control group exhibiting severe hypoglycemia (blood glucose &lt;40",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      [2.22",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that there are no clear benefits to tight glycemic control in critically ill children. Until further data are available, insulin therapy is warranted to avoid long periods of hyperglycemia &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9.99",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    while also avoiding hypoglycemia. We do",
"    <strong>",
"     not",
"    </strong>",
"    advocate tight glycemic control. However, there is no universally accepted insulin regimen, and the optimal approach to hyperglycemia in children with septic shock awaits further study.",
"   </p>",
"   <p>",
"    Glycemic control in adults with critical illness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link&amp;anchor=H5#H5\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270368\">",
"    <span class=\"h2\">",
"     Avoid hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate calcium stores are essential for maintaining myocardial contractility. Thus, ionized blood calcium levels should be monitored every one to two hours during initial management of septic shock. Patients with persistent shock and an ionized calcium &lt;1.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (4.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or those with symptomatic hypocalcemia (eg, positive Chvostek or Trousseau signs, seizures, prolonged QT interval on EKG, or cardiac arrhythmias) in association with a an ionized calcium &lt;1.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (4.8",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    should undergo correction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    10 percent solution in a dose of 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mL/kg),",
"    </span>",
"    maximum dose 2 g (20 mL) by slow intravenous or intraosseous infusion over five minutes. This suggested dose is equivalent to elemental calcium 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mmol/kg),",
"    </span>",
"    up to 180 mg elemental (4.5 mmol) per single dose",
"    <br/>",
"    <br/>",
"    Calcium should be administered in a larger vein or, preferably, a central line.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be introduced into the IV or IO without flushing before and after administration because of potential precipitation.",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"     Calcium chloride",
"    </a>",
"    10 percent in a dose of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mL/kg),",
"    </span>",
"    maximum dose 1 g (10 mL) provides an equivalent dose but should",
"    <strong>",
"     only",
"    </strong>",
"    be administered through a central line. Patients receiving a calcium infusion warrant continuous cardiac monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270382\">",
"    <span class=\"h2\">",
"     Treat known hormonal deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with septic shock who are receiving replacement therapy for adrenal insufficiency should receive stress doses of corticosteroids. (See",
"    <a class=\"local\" href=\"#H18270403\">",
"     'Address adrenal insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, children with septic shock and hypothyroidism should continue to receive thyroid replacement with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     levothyroxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of congenital hypothyroidism\", section on 'Dose of L-T4'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H22#H22\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'T4 dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270389\">",
"    <span class=\"h1\">",
"     REFRACTORY SEPTIC SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of septic shock including management recommendations for fluid-refractory septic shock are described in the algorithm and discussed in detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fluid-refractory, catecholamine-resistant shock is defined as cardiovascular dysfunction despite at least 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of fluid resuscitation and dopamine &ge;10",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    direct-acting catecholamines (epinephrine, norepinephrine). Principles of management for children with refractory septic shock include treatment of reversible etiologies, stress dose corticosteroid therapy for patients with absolute adrenal insufficiency, and combination vasoactive drug therapy targeted to maintaining central venous oxygen saturation &ge;70 percent and normalizing blood lactate levels.",
"   </p>",
"   <p>",
"    Although cardiac index targets are mentioned in previous pediatric septic shock guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"     24",
"    </a>",
"    ], evidence of improved outcomes from routine measurement of cardiac index is lacking (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ). If performed, the target range is 3.3 to 6.0",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270396\">",
"    <span class=\"h2\">",
"     Treat reversible etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax, pericardial tamponade, and intra-abdominal hypertension (eg, peritonitis or ascites) comprise mechanical causes of shock that can be reversed by chest tube thoracostomy, pericardiocentesis, or abdominal decompression surgery, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H254982395#H254982395\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Tube thoracostomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link&amp;anchor=H24600630#H24600630\">",
"     \"Emergency pericardiocentesis\", section on 'Technique overview'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Drainage or debridement of infection sites (eg, necrotizing fasciitis) or broadening of antimicrobial coverage are additional actions that may be warranted. (See",
"    <a class=\"local\" href=\"#H18270333\">",
"     'Eradicate infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H22#H22\">",
"     \"Necrotizing soft tissue infections\", section on 'Treatment'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Uncontrolled hemorrhage, typically caused by spontaneous bleeding secondary to disseminated intravascular coagulopathy warrants timely administration of blood and blood products. (See",
"    <a class=\"local\" href=\"#H1584851\">",
"     'Treat disseminated intravascular coagulation'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p>",
"    In rare instances, persistent shock may reflect anaphylaxis to administered antibiotic agents. These patients warrant treatment with antihistamines, epinephrine, corticosteroids, and removal of the inciting agent (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17141810\">",
"    <span class=\"h2\">",
"     Obtain cardiac evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with refractory septic shock warrant an electrocardiogram to assess for signs of myocardial ischemia or infarction and heart failure. Pediatric cardiology consultation and echocardiography is also advised to assess for signs of myocarditis or, especially in neonates and young infants, signs of congenital heart disease.",
"   </p>",
"   <p>",
"    Patients with myocarditis diagnosed by endomyocardial biopsy may benefit from intravenous gamma globulin, although evidence is very limited. Corticosteroids or other immunosuppressive agents may be appropriate for patients with myocarditis caused by systemic autoimmune disease in addition to infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2647?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of myocarditis in children\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270403\">",
"    <span class=\"h2\">",
"     Address adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal insufficiency is a clinical condition frequently associated with fluid- and catecholamine-resistant septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24,30,31\">",
"     24,30,31",
"    </a>",
"    ]. We suggest that children with fluid-refractory, catecholamine-resistant septic shock receive stress dose glucocorticoids (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per",
"    <strong>",
"     dose",
"    </strong>",
"    or 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [maximum 100 mg] per",
"    <strong>",
"     dose",
"    </strong>",
"    followed by 50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [maximum 100 mg] per",
"    <strong>",
"     day",
"    </strong>",
"    either given continuously or divided every four or six hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/12,24,32-35\">",
"     12,24,32-35",
"    </a>",
"    ]. Corticosteroid therapy should be discontinued when the patient becomes hemodynamically stable and no longer requires vasoactive medication administration. Practice varies regarding whether corticosteroids are abruptly discontinued or tapered in children with septic shock. Adult guidelines suggest tapering of corticosteroids but there is insufficient data in children. However, tapering is suggested if duration of corticosteroid use is long enough to potentially have caused adrenal suppression or adrenal suppression is identified by provocative testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link&amp;anchor=H19#H19\">",
"     \"Corticosteroid therapy in septic shock\", section on 'Administration'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Stress-dose corticosteroids should",
"    <strong>",
"     not",
"    </strong>",
"    be given to children with septic shock who never required or who no longer require vasopressor support unless the patient has pre-existing known adrenal insufficiency.",
"   </p>",
"   <p>",
"    Whether to use baseline cortisol measurements, adrenocorticotropin stimulation testing, or persistent hemodynamic instability alone as indicators for initiating and continuing corticosteroid therapy in children with refractory septic shock is debated and evidence for the best approach is lacking.",
"   </p>",
"   <p>",
"    Adrenal insufficiency (AI) is often defined in the critically ill pediatric population by an insufficient response to an adrenocorticotropic hormone (ACTH) stimulation test with a change in cortisol from baseline to one hour after the intravenous cosyntropin of &lt;9",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    Using this definition, one multicenter study showed that 30 percent of 381 critically ill children met criteria for AI during the first day of intensive care with a similar frequency occurring in the 59 patients with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients receiving catecholamines had a higher rate of AI (43 percent). The median baseline cortisol was 28.6",
"    <span class=\"nowrap\">",
"     ug/dL",
"    </span>",
"    in the children with AI, versus 16.7 in those without AI. Among patients who did not receive corticosteroids and were re-tested 24 hours later, &lt;20 percent met criteria for AI. Thus, AI can exist in critically ill patients with a relatively high random cortisol level, and AI can resolve without specific treatment. These findings have led some experts to suggest the use of stress dose corticosteroids in children with refractory septic shock without specific testing for AI.",
"   </p>",
"   <p>",
"    Corticosteroids are not without risk and should not be routinely used in children with septic shock. In an observational study of 6693 children with severe sepsis treated in children&rsquo;s hospitals, corticosteroid treatment was associated with clinically significantly increased mortality (adjusted odds ratio 1.9 [95% CI 1.7, 2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/37\">",
"     37",
"    </a>",
"    ]. Neonates who received &ge;2 days of corticosteroids had a greater absolute increase in mortality than older patients (12 percent versus 6 percent increased mortality). Thus, further evidence is needed to better guide the use of corticosteroid administration in children with septic shock, including those patients who are most likely to benefit or experience adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270410\">",
"    <span class=\"h2\">",
"     Combination vasoactive drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ongoing management of vasoactive drug therapy in children with septic shock should be performed by clinicians with pediatric critical care expertise whenever possible. The approach provided here is for patients with septic shock who have already received a rapid infusion of at least 40 to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of crystalloid and continuous infusions of dopamine or epinephrine (patients with cold shock) or norepinephrine (patients with warm shock) (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The physical findings of cold and warm shock are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H1374189#H1374189\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional vasoactive therapy should be based upon the type of persistent shock (cold or warm shock) and the central venous oxygen saturation (ScvO",
"    <sub>",
"     2",
"    </sub>",
"    ) as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Warm shock with low blood pressure,",
"      </strong>",
"      <strong>",
"       ScvO",
"      </strong>",
"      <strong>",
"       <sub>",
"        2",
"       </sub>",
"      </strong>",
"      <strong>",
"       &lt;70 percent",
"      </strong>",
"      &ndash; If initially receiving dopamine, addition of a norepinephrine infusion is warranted. Patients who do not respond to norepinephrine infusion may receive vasopressin or its long-acting formulation, terlipressin, if available, although use of these agents is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"       24",
"      </a>",
"      ]. Case reports, case series, and one trial indicate that administration of either vasopressin or terlipressin is associated with an increase in mean arterial blood pressure and urine output in children with fluid-refractory, catecholamine-resistant septic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. However, in a multicenter trial of 65 children with vasodilatory shock, low-dose vasopressin did not decrease the time to hemodynamic stability off vasopressor agents versus placebo (49.7 versus 47.1 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients receiving low-dose vasopressin had higher mortality (30 versus 16 percent) although this difference was not statistically significant.",
"     </li>",
"     <li>",
"      <strong>",
"       Cold shock with normal or low blood pressure, ScvO",
"      </strong>",
"      <strong>",
"       <sub>",
"        2",
"       </sub>",
"      </strong>",
"      <strong>",
"       &lt;70 percent",
"      </strong>",
"      &ndash; If initially receiving dopamine, addition of an epinephrine infusion is warranted.",
"      <br/>",
"      <br/>",
"      If ScvO",
"      <sub>",
"       2",
"      </sub>",
"      remains below 70 percent, addition of agents with inotropic properties and afterload reduction (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"       dobutamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"       milrinone",
"      </a>",
"      ) or rapid-acting vasodilators for afterload reduction (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ) may be helpful (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/12\">",
"       12",
"      </a>",
"      ]. Since hypotension could be exacerbated by addition of vasodilating agents, these should be titrated carefully with close attention to hemodynamic changes. Vasodilators should be discontinued if hypotension worsens.",
"      <br/>",
"      <br/>",
"      In a small trial of 12 children with refractory catecholamine-resistant shock, administration of milrinone was associated with improved cardiac index and increased oxygen delivery although improved survival was not demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/42\">",
"       42",
"      </a>",
"      ]. Milrinone is a phosphodiesterase inhibitor that provides both increased cardiac contractility and vasodilation with afterload reduction. However, long-term use of milrinone is associated with an increased frequency of ventricular arrhythmias, including torsade des pointes. Patients receiving milrinone warrant close monitoring for hypotension, given its long half life.",
"      <br/>",
"      <br/>",
"      Alternatively, use of a vasodilator (eg, nitroprusside) for afterload reduction may be beneficial in selected patients. If nitroprusside is used, the medication should be protected from light, and doses in excess of 1.8",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute should be avoided. Concomitant administration of thiosulfate to scavenge the cyanide produced by nitroprusside metabolism is suggested, either prophylactically or if cyanide levels are elevated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270424\">",
"    <span class=\"h2\">",
"     Advanced therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270431\">",
"    <span class=\"h3\">",
"     Extracorporeal membrane oxygenation (ECMO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and the American College of Critical Care Medicine (ACCM) suggest that children with persistent catecholamine-resistant shock in whom physiologic targets (eg, ScvO",
"    <sub>",
"     2",
"    </sub>",
"    &ge;70 percent)",
"    <sup>",
"    </sup>",
"    cannot be attained with fluid repletion, vasoactive infusion, and hormonal therapy; who do not have an immediately reversible cause, such as myocarditis, pneumothorax, or pericardial effusion; and who have a high likelihood of mortality, be evaluated for extracorporeal membrane oxygenation (ECMO) support, if available (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/12\">",
"     12",
"    </a>",
"    ]. If ECMO is not available at the facility in which the child is receiving care then the potential benefits of ECMO must be weighed against the likelihood that the patient can tolerate transfer.",
"   </p>",
"   <p>",
"    Severe sepsis and septic shock were previously considered to be contraindications to extracorporeal membrane oxygenation (ECMO) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"     24",
"    </a>",
"    ]. However, more recent data suggest that for patients who receive ECMO, survival to hospital discharge approaches 50 percent in pediatric refractory septic shock and 80 percent for neonatal refractory septic shock. As an example, in a small case series of 23 children with refractory septic shock in which central cannulation was used to achieve higher blood flow rates, 18 (78 percent) patients survived to be decannulated off ECMO and 17 (74 percent) children survived to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/43\">",
"     43",
"    </a>",
"    ]. Our experience suggests that the chances of survival in such patients with conventional therapy alone are otherwise very remote.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270439\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant therapy with intravenous immune globulin (IVIG) has been proposed but evidence for benefit in children with septic shock remains inconclusive. A trial of polyclonal IVIG in 100 children with pediatric sepsis syndrome showed a significant reduction in mortality (28 versus 44 percent), length of stay (six versus nine days), and less progression to complications (8 versus 32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a more recent multicenter trial of polyclonal IVIG in 3493 neonates receiving antibiotics for suspected or proven serious infection found no significant difference in the rate of the primary outcome of death or major disability at the age of two years (relative risk, 1.00; 95% CI, 0.9 to 1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/45\">",
"     45",
"    </a>",
"    ]. Evidence in adult patients with septic shock suggests that IVIG has no benefit in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link&amp;anchor=H4#H4\">",
"     \"Investigational and ineffective therapies for sepsis\", section on 'Intravenous immunoglobulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with toxic shock syndrome, IVIG may have clinical utility. IVIG for this indication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link&amp;anchor=H27#H27\">",
"     \"Staphylococcal toxic shock syndrome\", section on 'Intravenous immune globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270446\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270453\">",
"    <span class=\"h2\">",
"     Plasma exchange or plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable interest in extracorporeal filtration of circulating inflammatory mediators in sepsis. Although multiple studies in adults have been published on plasma exchange and plasmapheresis in sepsis, most are limited by small sample size at single institutions with considerable variability in the protocols utilized. Thus, current evidence is conflicting as to clinical benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link&amp;anchor=H12#H12\">",
"     \"Investigational and ineffective therapies for sepsis\", section on 'Hemofiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the practical limitations of inserting a large catheter for plasma exchange in young children (often with disseminated intravascular coagulopathy and increased risk of bleeding), the intensive resources necessary to perform plasma exchange or plasmapheresis, and the potential to worsen hypotension in hemodynamically unstable patients has limited this therapy in pediatric sepsis.",
"   </p>",
"   <p>",
"    One small trial of 10 children demonstrated a survival benefit in patients with the clinical phenotype of thrombocytopenia-associated multiple organ failure or TAMOF receiving plasmapheresis versus standard therapy (five of five versus one of five surviving) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/46\">",
"     46",
"    </a>",
"    ]. In this study, low levels of the von Willebrand factor cleaving protease, ADAMTS-13, activity were reversed with daily plasma exchange, which the authors suggested as the potential benefit of this therapy. Until further data becomes available, plasma exchange for pediatric patients with sepsis, including TAMOF with decreased ADAMTS-13 activity, remains an experimental therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270460\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of therapies have been investigated or are being evaluated to improve clinical outcomes in sepsis. Those therapies that appear promising as well as ones that have been proven to be ineffective are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link\">",
"     \"Investigational and ineffective therapies for sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270467\">",
"    <span class=\"h1\">",
"     GUIDELINE IMPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early recognition and management of pediatric severe sepsis and septic shock can be improved through the establishment of institutional care guidelines. As an example, in an observational study of the impact of guidelines for sepsis management in a children&rsquo;s hospital emergency department versus baseline actions before implementation, significant gains were documented for several key therapeutic actions including more timely fluid resuscitation (70 versus 43 percent receiving 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of normal saline in the first hour), antibiotic administration (90 versus 53 percent receiving antibiotics within three hours), and blood lactate determination (measured in 70 versus 10 percent of patients with possible septic shock) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/47\">",
"     47",
"    </a>",
"    ]. Median length of hospital stay decreased clinically significantly after implementation of the guidelines (181 to 140 hours). Mortality was not significantly different (6 versus 7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270474\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors related to the host, site of infections, and microbiology may influence the progression from systemic inflammatory response syndrome to severe sepsis to septic shock and provide predictors of mortality. Severity of illness, progression to multiple organ failure, and treatment requirements are also important prognostic indicators:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Host factors",
"      </strong>",
"      &ndash; Case fatality rates in children with severe sepsis are highest for infants 1 to 12 months of age (approximately 11 percent) and are higher across all age groups for children with comorbidities, especially in children with cancer or human immunodeficiency virus infection (12 to 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/3,48\">",
"       3,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Site of infection",
"      </strong>",
"      &ndash; Children with endocarditis, central nervous system infection, and primary bacteremia have high case fatality rates (15 to 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/3\">",
"       3",
"      </a>",
"      ]. The case fatality rate is lowest for genitourinary tract infections (approximately 4 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       Microbiology",
"      </strong>",
"      &ndash; Case fatality is increased in children with pneumococcal and fungal infections (15 and 13 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/3\">",
"       3",
"      </a>",
"      ]. Infection with organisms resistant to antibiotics (eg, methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococcus species) is associated with a marked increased mortality from sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H20#H20\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Type of infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Severity of illness",
"      </strong>",
"      &ndash; Mortality increases markedly depending upon the severity of illness in children with sepsis. As an example, in a multicenter observational study of 1051 children between one month and 18 years of age treated for sepsis in pediatric ICUs, mortality increased from 1 percent in children with sepsis to 6 percent and 34 percent in children with severe sepsis and septic shock, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple organ failure",
"      </strong>",
"      &ndash; The development of multiple organ dysfunction indicates an increased severity of illness in patients with sepsis and is associated with a higher mortality estimated as 0 to 7 percent for patients with one affected organ system and 20 to 50 percent with two or more failing organ systems [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/3,48-50\">",
"       3,48-50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H1373466#H1373466\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Sepsis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment requirements",
"      </strong>",
"      &ndash; The need for multiple vasoactive infusions predicts a poor prognosis. As an example, in an observational study of 96 episodes of pediatric septic shock in 80 patients, mortality was significantly higher for patients receiving multiple rather than one vasoactive agent (43 versus 0 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/2/13354/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18270481\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rapid recognition and initial resuscitation of children with septic shock is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ongoing aggressive resuscitation should continue after the initial resuscitation of pediatric septic shock according to the principles of goal-directed therapy, especially when managing children in whom adequate circulation has not been restored (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18270326\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, children requiring resuscitation for septic shock should receive ongoing management by a pediatric critical care specialist or pediatrician with similar expertise in a pediatric intensive care unit. (See",
"      <a class=\"local\" href=\"#H18270326\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eradication of infection can reverse septic shock. Antimicrobial treatment should be optimized based upon culture results. Source control (physical measures undertaken to eradicate a focus of infection, to eliminate ongoing microbial contamination, and to render a site inhospitable to microbial growth and invasion) should be undertaken when possible because localized foci of infection (ie, abscess) may not respond to antibiotics alone (",
"      <a class=\"graphic graphic_table graphicRef59769 \" href=\"UTD.htm?2/26/2477\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18270333\">",
"       'Eradicate infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During initial management, continuation of respiratory support, monitoring of tissue perfusion using physiologic indicators and target goals, aggressive administration of fluids, and titration of vasoactive infusions continue. In addition, the clinician should determine the need for invasive monitoring via intraarterial and central venous cannulas. (See",
"      <a class=\"local\" href=\"#H18270340\">",
"       'Ongoing and invasive monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H6411955#H6411955\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Physiologic indicators and target goals'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H18270347\">",
"       'Continue fluid administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintaining adequate hemoglobin levels is a critical aspect of managing children with septic shock. We and the American College of Critical Care Medicine (ACCM) guidelines suggest a hemoglobin goal of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (equivalent to 30 percent hematocrit) as a target to maintain with blood transfusion during resuscitation and ongoing management of children with septic shock (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Once shock has resolved, a lower hematocrit threshold for blood transfusion may be safe. (See",
"      <a class=\"local\" href=\"#H18270354\">",
"       'Blood transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelets, fresh frozen plasma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cryoprecipitate should be provided to patients with disseminated intravascular coagulopathy and significant bleeding. (See",
"      <a class=\"local\" href=\"#H1584851\">",
"       'Treat disseminated intravascular coagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other important interventions include management of glucose abnormalities, treatment of symptomatic hypocalcemia, and replacement therapy for known adrenal insufficiency or hypothyroidism. (See",
"      <a class=\"local\" href=\"#H18270361\">",
"       'Manage glucose abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18270368\">",
"       'Avoid hypocalcemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18270382\">",
"       'Treat known hormonal deficiencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Principles of management for children with refractory septic shock include (see",
"      <a class=\"local\" href=\"#H18270389\">",
"       'Refractory septic shock'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment of reversible causes (eg, pneumothorax, pericardial tamponade, hemorrhage)",
"     </li>",
"     <li>",
"      Assessment for and treatment of adrenal insufficiency",
"     </li>",
"     <li>",
"      Combination vasoactive therapy targeted to central venous oxygen saturation and other measures of tissue perfusion (eg, capillary refill time, urine output, mental status, and serum lactate levels)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that children with refractory catecholamine-resistant septic shock receive stress dose corticosteroids (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      50 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per",
"      <strong>",
"       dose",
"      </strong>",
"      or 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [maximum 100 mg] per",
"      <strong>",
"       dose",
"      </strong>",
"      followed by 50 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [maximum 100 mg] per",
"      <strong>",
"       day",
"      </strong>",
"      either given continuously or divided every four or six hours) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Whether to use baseline cortisol measurements, adrenocorticotropin stimulation testing, or persistent hemodynamic instability alone as indicators for continued therapy is debated and evidence for the best approach in children is lacking. Corticosteroid therapy should be discontinued when the patient becomes hemodynamically stable. Stress-dose corticosteroids should not be given to children with septic shock who never required or who no longer require vasopressor support unless the patient has pre-existing known adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H18270403\">",
"       'Address adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We and the ACCM guidelines suggest that children with persistent catecholamine-resistant shock in whom physiologic targets (eg, ScvO",
"      <sub>",
"       2",
"      </sub>",
"      &ge;70 percent)",
"      <sup>",
"      </sup>",
"      cannot be attained with fluid repletion, vasoactive infusion, and hormonal therapy; who do not have a reversible cause, such as myocarditis, pneumothorax, or pericardial effusion; and who have a high likelihood of mortality, be evaluated for extracorporeal membrane oxygenation (ECMO) support, if available (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the patient is an ECMO candidate and ECMO is not available at the facility in which the child is receiving care then the potential benefits of ECMO must be weighed against the likelihood that the patient can tolerate transfer. (See",
"      <a class=\"local\" href=\"#H18270431\">",
"       'Extracorporeal membrane oxygenation (ECMO)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/1\">",
"      Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/2\">",
"      Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/3\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/4\">",
"      Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/5\">",
"      Weiss SL, Parker B, Bullock ME, et al. Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice. Pediatr Crit Care Med 2012; 13:e219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/6\">",
"      Jaramillo-Bustamante JC, Mar&iacute;n-Agudelo A, Fern&aacute;ndez-Laverde M, Bare&ntilde;o-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/7\">",
"      Kutko MC, Glick RD, Butler LM, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003; 9:5749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/8\">",
"      Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/9\">",
"      Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/10\">",
"      Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/11\">",
"      Randolph AG. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009; 37:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/12\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/13\">",
"      Santschi M, Jouvet P, Leclerc F, et al. Acute lung injury in children: therapeutic practice and feasibility of international clinical trials. Pediatr Crit Care Med 2010; 11:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/14\">",
"      Hanson JH, Flori H. Application of the acute respiratory distress syndrome network low-tidal volume strategy to pediatric acute lung injury. Respir Care Clin N Am 2006; 12:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/15\">",
"      Holt TR, Withington DE, Mitchell E. Which pressure to believe? A comparison of direct arterial with indirect blood pressure measurement techniques in the pediatric intensive care unit. Pediatr Crit Care Med 2011; 12:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/16\">",
"      Fernandez EG, Green TP, Sweeney M. Low inferior vena caval catheters for hemodynamic and pulmonary function monitoring in pediatric critical care patients. Pediatr Crit Care Med 2004; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/17\">",
"      Yung M, Butt W. Inferior vena cava pressure as an estimate of central venous pressure. J Paediatr Child Health 1995; 31:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/18\">",
"      Carcillo JA, Fields AI, American College of Critical Care Medicine Task Force Committee Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/19\">",
"      Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004; 32:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/20\">",
"      Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010; 55:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/21\">",
"      Karam O, Tucci M, Ducruet T, et al. Red blood cell transfusion thresholds in pediatric patients with sepsis. Pediatr Crit Care Med 2011; 12:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/22\">",
"      Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/23\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Gluud C, et al. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 2012; 12:CD004388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/24\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/25\">",
"      Branco RG, Garcia PC, Piva JP, et al. Glucose level and risk of mortality in pediatric septic shock. Pediatr Crit Care Med 2005; 6:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/26\">",
"      van Waardenburg DA, Jansen TC, Vos GD, Buurman WA. Hyperglycemia in children with meningococcal sepsis and septic shock: the relation between plasma levels of insulin and inflammatory mediators. J Clin Endocrinol Metab 2006; 91:3916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/27\">",
"      Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009; 373:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/28\">",
"      Mesotten D, Gielen M, Sterken C, et al. Neurocognitive development of children 4 years after critical illness and treatment with tight glucose control: a randomized controlled trial. JAMA 2012; 308:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/29\">",
"      Agus MS, Steil GM, Wypij D, et al. Tight glycemic control versus standard care after pediatric cardiac surgery. N Engl J Med 2012; 367:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/30\">",
"      Sarthi M, Lodha R, Vivekanandhan S, Arora NK. Adrenal status in children with septic shock using low-dose stimulation test. Pediatr Crit Care Med 2007; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/31\">",
"      Zimmerman JJ. Moving beyond Babel. Pediatr Crit Care Med 2007; 8:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/32\">",
"      Parker MM, Hazelzet JA, Carcillo JA. Pediatric considerations. Crit Care Med 2004; 32:S591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/33\">",
"      Melendez E, Bachur R. Advances in the emergency management of pediatric sepsis. Curr Opin Pediatr 2006; 18:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/34\">",
"      Hauser, GJ. Early goal-directed therapy of pediatric septic shock in the emergency department. Isr J Emerg Med 2007; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/35\">",
"      Langer M, Modi BP, Agus M. Adrenal insufficiency in the critically ill neonate and child. Curr Opin Pediatr 2006; 18:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/36\">",
"      Menon K, Ward RE, Lawson ML, et al. A prospective multicenter study of adrenal function in critically ill children. Am J Respir Crit Care Med 2010; 182:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/37\">",
"      Markovitz BP, Goodman DM, Watson RS, et al. A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids? Pediatr Crit Care Med 2005; 6:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/38\">",
"      Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med 2008; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/39\">",
"      Meyer S, Gortner L, McGuire W, et al. Vasopressin in catecholamine-refractory shock in children. Anaesthesia 2008; 63:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/40\">",
"      Masutani S, Senzaki H, Ishido H, et al. Vasopressin in the treatment of vasodilatory shock in children. Pediatr Int 2005; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/41\">",
"      Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med 2009; 180:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/42\">",
"      Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996; 109:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/43\">",
"      MacLaren G, Butt W, Best D, Donath S. Central extracorporeal membrane oxygenation for refractory pediatric septic shock. Pediatr Crit Care Med 2011; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/44\">",
"      El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr 2005; 51:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/45\">",
"      INIS Collaborative Group, Brocklehurst P, Farrell B, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/46\">",
"      Nguyen TC, Han YY, Kiss JE, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008; 36:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/47\">",
"      Larsen GY, Mecham N, Greenberg R. An emergency department septic shock protocol and care guideline for children initiated at triage. Pediatrics 2011; 127:e1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/48\">",
"      Kutko MC, Calarco MP, Flaherty MB, et al. Mortality rates in pediatric septic shock with and without multiple organ system failure. Pediatr Crit Care Med 2003; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/49\">",
"      Proulx F, Fayon M, Farrell CA, et al. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996; 109:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/2/13354/abstract/50\">",
"      Graciano AL, Balko JA, Rahn DS, et al. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med 2005; 33:1484.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86881 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13354=[""].join("\n");
var outline_f13_2_13354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18270481\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18272002\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1585416\">",
"      RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270326\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270333\">",
"      Eradicate infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H627387\">",
"      Continue respiratory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270340\">",
"      Ongoing and invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270347\">",
"      Continue fluid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18272996\">",
"      - Fluid overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270354\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1584851\">",
"      Treat disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270361\">",
"      Manage glucose abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270368\">",
"      Avoid hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270382\">",
"      Treat known hormonal deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270389\">",
"      REFRACTORY SEPTIC SHOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270396\">",
"      Treat reversible etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17141810\">",
"      Obtain cardiac evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270403\">",
"      Address adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270410\">",
"      Combination vasoactive drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270424\">",
"      Advanced therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18270431\">",
"      - Extracorporeal membrane oxygenation (ECMO)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18270439\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270446\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270453\">",
"      Plasma exchange or plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18270460\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270467\">",
"      GUIDELINE IMPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270474\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18270481\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/86881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/86881|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/36/29255\" title=\"algorithm 1\">",
"      Pediatric sepsis management guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/86881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/26/2477\" title=\"table 1\">",
"      Evaluation of sources of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/43/32446\" title=\"table 2\">",
"      Rapid overview for hypoglycemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 3\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=related_link\">",
"      Arterial puncture and cannulation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=related_link\">",
"      Investigational and ineffective therapies for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2647?source=related_link\">",
"      Treatment and prognosis of myocarditis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_2_13355="Mitochondrial dysfunction";
var content_f13_2_13355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms of mitochondrial dysfunction associated with antiretroviral agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        NRTI side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyneuropathy",
"       </td>",
"       <td>",
"        d4T, ddI, ddC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myopathy",
"       </td>",
"       <td>",
"        AZT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy",
"       </td>",
"       <td>",
"        AZT, d4T",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic steatosis, lactic acidosis",
"       </td>",
"       <td>",
"        AZT, ddI, d4T",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"       <td>",
"        ddI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancytopenias",
"       </td>",
"       <td>",
"        AZT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipodystrophy",
"       </td>",
"       <td>",
"        d4T, AZT",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NRTI: nucleoside reverse transcriptase inhibitor; d4T: stavudine; ddI: didanosine; ddC: zalcitabine (no longer available); AZT: zidovudine.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13355=[""].join("\n");
var outline_f13_2_13355=null;
var title_f13_2_13356="Seizure diary PI";
var content_f13_2_13356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Seizure diary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        After your child has a seizure, try to answer the following questions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Did the seizure occur at night or when the child was asleep, falling asleep, or upon awakening?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Was the child taking medication (prescription or over-the-counter) or herbs before the seizure?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Did the child have facial or arm/leg twitching before the seizure?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Does the child always cry before a seizure?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Are there any seizure triggers? (examples, strong emotions, intense exercise, certain sounds or music, and flashing lights)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Do one or both arms or legs move during the seizure, and if so, which side?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Were the child's eyes and mouth open or closed during the seizure?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Could the child respond to your voice? To being pinched?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Did the child's color change (eg, pale or blue) during the seizure?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          How long did the episode last?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          How did the child behave after the seizure? Did he or she recover immediately, or was there confusion or sleepiness? Did the child speak normally? Was the child able to move normally after the seizure? Did the child have any difficulty moving the arms or legs on one or both sides?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Did the child remember having the seizure or the events that occurred during it?",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13356=[""].join("\n");
var outline_f13_2_13356=null;
var title_f13_2_13357="ENETS staging system for pancreatic NETS";
var content_f13_2_13357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ENETS staging system for pancreatic neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        TNM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        T - primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <em>",
"         For any T, add (m) for multiple tumors",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor limited to pancreas and size &lt;2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor limited to the pancreas and size 2-4 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor limited to the pancreas and size &gt;4 cm or invading duodenum or bile duct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or superior mesenteric artery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        N - regional lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph node cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        M - distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MX",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastases",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        M1",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Disease stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage I",
"       </td>",
"       <td class=\"centered\">",
"        T1",
"       </td>",
"       <td class=\"centered\">",
"        N0",
"       </td>",
"       <td class=\"centered\">",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IIa",
"       </td>",
"       <td class=\"centered\">",
"        T2",
"       </td>",
"       <td class=\"centered\">",
"        N0",
"       </td>",
"       <td class=\"centered\">",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IIb",
"       </td>",
"       <td class=\"centered\">",
"        T3",
"       </td>",
"       <td class=\"centered\">",
"        N0",
"       </td>",
"       <td class=\"centered\">",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IIIa",
"       </td>",
"       <td class=\"centered\">",
"        T4",
"       </td>",
"       <td class=\"centered\">",
"        N0",
"       </td>",
"       <td class=\"centered\">",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IIIb",
"       </td>",
"       <td class=\"centered\">",
"        Any T",
"       </td>",
"       <td class=\"centered\">",
"        N1",
"       </td>",
"       <td class=\"centered\">",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IV",
"       </td>",
"       <td class=\"centered\">",
"        Any T",
"       </td>",
"       <td class=\"centered\">",
"        Any N",
"       </td>",
"       <td class=\"centered\">",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TNM: tumor, nodes, metastasis.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Sobin LH, Wittekind C (Eds). TNM classification of malignant tumours. Wiley-Liss, New York, 2002.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: Rindi G, Kloppel H, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395. Copyright &copy; 2006; with kind permission from Springer Science + Business Media B.V.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13357=[""].join("\n");
var outline_f13_2_13357=null;
var title_f13_2_13358="Apoptosis in thalassemia";
var content_f13_2_13358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apoptosis in thalassemia variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These graphs show the percentage of erythroid precursors undergoing apoptosis (mean &plusmn; 1 SD) in normal controls and in patients from Thailand with clinical diagnoses of &alpha; and &beta; thalassemia, using both the annexin V and the Hoechst 33342 methodologies.",
"    <div class=\"footnotes\">",
"     hbH: hemoglobin H disease; H/CS: hemoglobin H/hemoglobin constant spring; CS/CS: homozygous hemoglobin constant spring; bthal/hbE: beta thalassemia/hemoglobin E disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pootrakul, P, et al. Blood 2000; 96:2610. Copyright &copy; 2000 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13358=[""].join("\n");
var outline_f13_2_13358=null;
var title_f13_2_13359="Applied PEEP and work";
var content_f13_2_13359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Applied PEEP and work",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 345px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airway pressure (Paw) and esophageal pressure (Pes) in a patient receiving mechanical ventilation with no PEEP (left panel) and PEEP of 8 cm H2O (right panel). The addition of PEEP decreases Pes fluctuation, indicating decrease in patient effort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jubran, A, Tobin, MJ. In: Principles and Practice of Mechanical Ventilation. Tobin, MJ (Ed), McGraw Hill, Inc. New York 2006. Copyright &copy;2006 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_2_13359=[""].join("\n");
var outline_f13_2_13359=null;
